Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer, Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Phase: PHASE2
Conditions: Prostatic Neoplasms
Sponsor: Janssen Research & Development, LLC

1 
Approved, Date: 19 February 2018  
 
Janssen Research & Development * 
 
 
 
Clinical Protocol 
 
Abiraterone acetate in patients with Metastatic Castration-Resistant Prostate Cancer, 
Chemo-naive, who received a prior Diethylstilbestrol therapy  
 
Protocol 212082PCR2036; Phase: 2 
Amendment INT-2 
 
 
 JNJ-212082 (abiraterone acetate)  
 
*Janssen Research & Development is a global organization that operates through different legal entities 
in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & 
Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; 
Janssen Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Infectious Diseases 
BVBA; Janssen R&D Ireland; or Janssen Research & Development, LLC. The term “sponsor” is used 
throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact 
Information page that accompanies the protocol.  
 
 
 
 
 
 
 
 
 
 
Status: 
Approved
Date:
19 February 2018
Prepared by: 
Janssen Research & Development, LLC  
 
 
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements.  
Confidentiality Statement 
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed 
by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential. 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
2 
Approved, Date: 19 February 2018  
TABLE OF CONTENTS  
PROTOCOL AMENDMENTS .................................................................................................... 5 
SYNOPSIS ................................................................................................................................. 8 
TIME AND EVENTS SCHEDULE ........................................................................................... 14 
ABBREVIATIONS ................................................................................................................... 16 
1. 
INTRODUCTION............................................................................................................. 18 
1.1. 
Background ................................................................................................................. 18 
1.1.1. 
The Rationale for Abiraterone Acetate in the Management of Castration-Resistant 
Prostate Cancer (CRPC) ......................................................................................... 18 
1.1.2. 
Abiraterone Acetate ................................................................................................. 19 
1.1.3. 
Clinical Experience with Abiraterone Acetate .......................................................... 19 
1.1.4. 
Clinical Experience with Abiraterone Acetate in CRPC chemo-naïve patients ....... 20 
1.2. 
Overall Rationale for the Study ................................................................................... 20 
2. 
OBJECTIVE AND HYPOTHESIS ................................................................................... 21 
2.1. 
Objectives ................................................................................................................... 21 
2.2. 
Hypothesis .................................................................................................................. 21 
3. 
STUDY DESIGN AND RATIONALE .............................................................................. 21 
3.1. 
Overview of Study Design ........................................................................................... 21 
4. 
SUBJECT POPULATION ............................................................................................... 22 
4.1. 
Inclusion Criteria ......................................................................................................... 22 
4.2. 
Exclusion Criteria ........................................................................................................ 24 
5. 
DOSAGE AND ADMINISTRATION ............................................................................... 25 
5.1. 
Planned Dose .............................................................................................................. 25 
5.2. 
Dose Modification and Management of Toxicity ......................................................... 25 
5.3. 
Guidelines for Abnormal Liver Function Test .............................................................. 26 
5.4. 
Guidelines for Hypertension, Hypokalemia and Fluid Retention/Edema Due to 
Mineralocorticoid Excess ............................................................................................ 26 
6. 
TREATMENT COMPLIANCE ......................................................................................... 27 
7. 
PRESTUDY AND CONCOMITANT THERAPY ............................................................. 27 
7.1. 
Permitted Supportive Care and Interventions ............................................................. 28 
7.2. 
Special Concomitant Therapy ..................................................................................... 28 
7.3. 
Prohibited Medications ................................................................................................ 29 
8. 
STUDY EVALUATIONS ................................................................................................. 29 
8.1. 
Study Procedures ........................................................................................................ 29 
8.1.1. 
Overview .................................................................................................................. 29 
8.1.2. 
Screening Phase ..................................................................................................... 29 
8.1.3. 
Study Visits .............................................................................................................. 30 
8.1.4. 
PSA Progression/Early Withdrawal ......................................................................... 30 
8.1.5. 
Post-PSA Progression (Follow-Up) ......................................................................... 30 
8.2. 
Efficacy ........................................................................................................................ 30 
8.2.1. 
Evaluations .............................................................................................................. 30 
8.2.2. 
Endpoints ................................................................................................................. 31 
8.2.2.1. 
Primary Endpoint .................................................................................................. 31 
8.2.2.2. 
Secondary Endpoints ........................................................................................... 31 
8.2.2.3. 
Brief Pain Inventory-Short Form (BPI-SF) ............................................................ 31 
8.3. 
Safety Evaluations ...................................................................................................... 32 
8.4. 
Sample Collection and Handling ................................................................................. 33 
9. 
SUBJECT COMPLETION/WITHDRAWAL .................................................................... 33 
9.1. 
Study Completion ........................................................................................................ 33 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
3 
Approved, Date: 19 February 2018  
9.2. 
Discontinuation of Study Treatment ............................................................................ 33 
9.3. 
Withdrawal from the Study .......................................................................................... 34 
10. 
STATISTICAL METHODS .............................................................................................. 34 
10.1. 
Subject Information ..................................................................................................... 35 
10.2. 
Sample Size Determination ........................................................................................ 35 
10.3. 
Demographics and Baseline Characteristics .............................................................. 35 
10.4. 
Efficacy Analyses ........................................................................................................ 35 
10.5. 
Biomarker Analyses .................................................................................................... 36 
10.6. 
Safety Analyses .......................................................................................................... 36 
11. 
ADVERSE EVENT REPORTING ................................................................................... 37 
11.1. 
Definitions ................................................................................................................... 37 
11.1.1. 
Adverse Event Definitions and Classifications ........................................................ 37 
11.1.2. 
Attribution Definitions ............................................................................................... 38 
11.1.3. 
Severity Criteria ....................................................................................................... 39 
11.2. 
Special Reporting Situations ....................................................................................... 39 
11.3. 
Procedures .................................................................................................................. 39 
11.3.1. 
All Adverse Events ................................................................................................... 39 
11.3.2. 
Serious Adverse Events .......................................................................................... 41 
11.3.3. 
Pregnancy ................................................................................................................ 42 
11.3.4. 
Contacting Sponsor Regarding Safety .................................................................... 42 
12. 
PRODUCT QUALITY COMPLAINT HANDLING ........................................................... 42 
12.1. 
Procedures .................................................................................................................. 42 
12.2. 
Contacting Sponsor Regarding Product Quality ......................................................... 43 
13. 
STUDY DRUG INFORMATION ...................................................................................... 43 
13.1. 
Physical Description of Study Drug(s) ........................................................................ 43 
13.2. 
Packaging ................................................................................................................... 43 
13.3. 
Labeling ....................................................................................................................... 43 
13.4. 
Preparation, Handling, and Storage ............................................................................ 43 
13.5. 
Drug Accountability ..................................................................................................... 43 
14. 
STUDY-SPECIFIC MATERIALS .................................................................................... 44 
15. 
ETHICAL ASPECTS ...................................................................................................... 44 
15.1. 
Study-Specific Design Considerations ........................................................................ 44 
15.2. 
Regulatory Ethics Compliance .................................................................................... 45 
15.2.1. 
Investigator Responsibilities .................................................................................... 45 
15.2.2. 
Independent Ethics Committee or Institutional Review Board ................................ 45 
15.2.3. 
Informed Consent .................................................................................................... 46 
15.2.4. 
Privacy of Personal Data ......................................................................................... 47 
15.2.5. 
Country Selection .................................................................................................... 48 
16. 
ADMINISTRATIVE REQUIREMENTS ........................................................................... 48 
16.1. 
Protocol Amendments ................................................................................................. 48 
16.2. 
Regulatory Documentation ......................................................................................... 48 
16.2.1. 
Regulatory Approval/Notification ............................................................................. 48 
16.2.2. 
Required Prestudy Documentation .......................................................................... 48 
16.3. 
Subject Identification, Enrollment, and Screening Logs ............................................. 49 
16.4. 
Source Documentation................................................................................................ 50 
16.5. 
Case Report Form Completion ................................................................................... 50 
16.6. 
Data Quality Assurance/Quality Control ..................................................................... 51 
16.7. 
Record Retention ........................................................................................................ 51 
16.8. 
Monitoring ................................................................................................................... 52 
16.9. 
Study Completion/Termination .................................................................................... 52 
16.9.1. 
Study Completion .................................................................................................... 52 
16.9.2. 
Study Termination .................................................................................................... 52 
16.10. On-Site Audits ............................................................................................................. 53 
16.11. Use of Information and Publication ............................................................................. 53 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
4 
Approved, Date: 19 February 2018  
REFERENCES ......................................................................................................................... 55 
ATTACHMENT 1: SUMMARY OF RECIST CRITERIA VERSION 1.1................................... 57 
Attachment 2: ECOG PERFORMANCE STATUS ................................................................... 64 
Attachment 3: NEW YORK HEART FAILURE CRITERIA ....................................................... 65 
Attachment 4: ADDITIONAL INFORMATION ON CYP450 DRUG INTERACTIONS ............. 66 
INVESTIGATOR AGREEMENT .............................................................................................. 67 
 
 
LIST OF ATTACHMENTS 
Attachment 1: SUMMARY OF RECIST CRITERIA VERSION 1.1 .......................................... 57 
Attachment 2: ECOG PERFORMANCE STATUS ................................................................... 64 
Attachment 3: NEW YORK HEART FAILURE CRITERIA ....................................................... 65 
Attachment 4: ADDITIONAL INFORMATION ON CYP450 DRUG INTERACTIONS ............. 66 
 
LIST OF IN-TEXT TABLES AND FIGURES 
TABLES 
Table 1: Timepoint Response: patients with Target (+/- no target) disease 1 ......................... 62 
Table 2: Timepoint Response: patients with non-target disease only i ................................... 63 
 
FIGURES 
Figure 1 – Study Flowchart 1 ................................................................................................... 22 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
5 
Approved, Date: 19 February 2018  
PROTOCOL AMENDMENTS 
 
Protocol Version  
Issue Date 
Original Protocol
10 Feb 2014
Amendment INT-1 
05 Dec 2014
Amendment INT-2
18 Jan 2018
 
Amendments are listed beginning with the most recent amendment. 
Amendment INT-2 (18 January 2018)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
The overall reason for the amendment: The overall reason for the amendment is to finalize 
follow-up/study, eliminating any unnecessary burden on the 
 
 
Applicable 
Section(s) 
Description of Change(s) 
Rationale: Original protocol visits and follow-up period were decided under assumptions 
made at the time of sample size calculation (ie: before trial start). A medium time of 8.5 
months was assumed to PSAP of Abiraterone plus prednisone in CRPC patients, which had 
failed to DES therapy, and a 5-month time to PSAP as the minimum effect to consider drug 
activity in this setting such as first-line chemotherapy. 
 
 
Janssen has performed an interim statistical analysis with proven efficacy of study drug and 
therefore accomplishing the primary objective of this protocol. Having reached the necessary 
number of events, additional patient visits or follow-up of the remaining 3 patients are not 
necessary for final statistical analysis. Therefore, this amendment is being proposed to 
finalize follow-up, eliminating any unnecessary burden on patients. 
Any patients still receiving study drug will continue to do so, if the physician considers 
beneficial to the patient, under a Continued Access Program, following the applicable 
regulations. Investigators will be trained on Janssen and regulatory pharmacovigilance 
requirements and patients will be followed for safety until 30 days after the last study drug 
dose.
Synopsis: Study 
design 
Change the sentence to clarify that treatment will continue until PSA 
progression, clinical progression, consent withdrawal, occurrence of 
unacceptable toxicity or study termination. 
Inclusion of sentence: In case of early study termination, any patients 
still receiving study drug will continue to do so, if the physician 
considers beneficial to the patient, under a Continued Access Program, 
following the applicable regulations. Investigators will be trained on 
Janssen and regulatory pharmacovigilance requirements and patients 
will be followed for safety until 30 days after the last study drug dose.
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
6 
Approved, Date: 19 February 2018  
Applicable 
Section(s) 
Description of Change(s) 
5.1. Planned dose 
Inclusion of sentence: In case of early study termination, any patients 
still receiving study drug will continue to do so, if the physician 
considers beneficial to the patient, under a Continued Access Program, 
following the applicable regulations. Investigators will be trained on 
Janssen and regulatory pharmacovigilance requirements and patients 
will be followed for safety until 30 days after the last study drug dose.
8.1.4. PSA 
Progression/Early 
Withdrawal
Inclusion of sentence: There is an expected data collection period of up 
to 24 months per patient after enrollment to monitor survival status and, 
if applicable, subsequent prostate cancer therapy.
8.1.5. Post-PSA 
Progression 
(Follow-up) 
Inclusion of sentence: In case of early study termination, any patients 
still receiving study drug will continue to do so, if the physician 
considers beneficial to the patient, under a Continued Access Program, 
following the applicable regulations. Investigators will be trained on 
Janssen and regulatory pharmacovigilance requirements and patients 
will be followed for safety until 30 days after the last study drug dose.
9.1. Study 
Completion 
Change the sentence to clarify expected data collection period. 
Inclusion of sentence: There is an expected data collection period of up 
to 24 months per patient after enrollment to monitor survival status and, 
if applicable, subsequent prostate cancer therapy.
16.9.2. Study 
termination 
Inclusion of additional reason for the early closure of investigational 
site: patients do not reach PSAP after at least 24 months of treatment 
and do not show clinical progressive results for more than 12 months.
 
Amendment INT-1 (05 December 2014)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
The overall reason for the amendment: The overall reason for the amendment is correct 
the Permitted Supportive Care and Interventions List.
 
Applicable 
Section(s) 
Description of Change(s) 
Rationale: Clarify that laboratory documents are the source data. Only actual dates of 
sample collection will be collected in eCRF.
8.4. Sample 
Collection and 
Handling
Change the sentence to clarify that laboratory documents are the source 
data and only actual dates of sample collection will be collected in 
eCRF
Rationale: Spironolactone is a prohibited medication.
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
7 
Approved, Date: 19 February 2018  
Applicable 
Section(s) 
Description of Change(s) 
7.1. Permitted 
Supportive Care 
and Interventions
Exclusion of spironolactone of Permitted Supportive Care and 
Interventions list. 
 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
8 
Approved, Date: 19 February 2018  
SYNOPSIS 
Abiraterone acetate in patients with Metastatic Castration-Resistant Prostate Cancer, 
Chemo-naive, who received a prior Diethylstilbestrol therapy  
STUDY DRUG 
ZYTIGA® (abiraterone acetate) is a prodrug of abiraterone, an irreversible inhibitor of 17α 
hydroxylase/C17, 20-lyase (cytochrome P450c17 [CYP17]), a key enzyme required for 
testosterone synthesis. Marketing authorization for ZYTIGA and prednisone/prednisolone was 
granted in April 2011 in the United States and in September 2011 in the European Union. 
Treatment with ZYTIGA improves survival in patients with metastatic castration-resistant 
prostate cancer. 
OBJECTIVES 
Primary 
The primary objective is to evaluate the efficacy, based on Prostate-specific antigen (PSA) 
progression, of Abiraterone acetate in patients with metastatic castration-resistant prostate 
cancer (mCRPC), chemo-naive, who received a prior Diethylstilbestrol Therapy (DES). 
Secondary 
The secondary objectives are to evaluate the clinically relevant Prostate-specific antigen (PSA) 
and survival improvements, safety of abiraterone acetate plus low-dose prednisone, as well as 
to explore the relationship between serum androgen levels and response to therapy. 
HYPOTHESIS 
Abiraterone acetate could be clinically effective and delay the start to chemotherapy in mCRPC 
patients who have progressed on DES therapy. 
STUDY DESIGN 
This is a phase II, multicenter, open-label, single arm study to determine if mCRPC patients 
who failed to prior DES therapy will benefit from the addition of abiraterone acetate and low-
dose prednisone to androgen deprivation therapy (ADT). In this study, ADT refers specifically 
to luteinizing hormone releasing hormone (LHRH) agonists or orchiectomy. Approximately 
45 subjects will be enrolled. The study population includes mCRPC adult men that might have 
undergone to a complete androgen blockage (CAB) and had failed to DES therapy.  
The study will consist of a Screening Phase of up to 28 days before enrollment to establish 
study eligibility and document baseline measurements; a PSA Evaluation Phase; and a Follow-
up Phase of up to 24 months to monitor survival status and subsequent prostate cancer therapy. 
Each cycle of abiraterone therapy is 28 days. Treatment will continue until PSA progression, 
clinical progression, consent withdrawal, occurrence of unacceptable toxicity or study 
termination. Patients experiencing PSA progression might be offered continuation on 
abiraterone treatment at the discretion of the investigator. Subjects who meet all of the inclusion 
criteria and none of the exclusion criteria will be enrolled to receive abiraterone acetate [1,000 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
9 
Approved, Date: 19 February 2018  
mg once daily] plus low-dose prednisone [5 mg once daily]. Patients need to be under ADT 
[LHRH agonist or orchiectomy] as per discretion of attending physician. 
Subjects will be monitored for safety throughout the study. Adverse events including laboratory 
adverse events will be graded and summarized using National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0. Dose modification 
guidelines are provided. 
In case of early study termination, any patients still receiving study drug will continue to do 
so, if the physician considers beneficial to the patient, under a Continued Access Program, 
following the applicable regulations. Investigators will be trained on Janssen and regulatory 
pharmacovigilance requirements and patients will be followed for safety until 30 days after the 
last study drug dose. 
SUBJECT SELECTION 
Inclusion  
1. 
Willing and able to provide written informed consent;  
2. 
Men age 18 years and older;  
3. 
Histologically or cytologically confirmed adenocarcinoma of the prostate without 
neuroendocrine differentiation or small cell histology; 
4. 
Prior therapy with DES for castration resistant prostate cancer. Patients should 
demonstrate evidence of progression (see below definitions) on DES or evidence of 
grades 3/4 toxicities on DES;  
5. 
Progressive disease: PSA progression per PCWG2 criteria (sequence of rising PSA 
values at least 1 week apart and minimum PSA level of 2 ng/mL) or radiographic 
progression per RECIST (version 1.1); 
6. 
Metastatic disease documented by positive bone scan or metastatic lesions on CT or 
MRI; 
7. 
Ongoing ADT (LHRH agonist or orchiectomy), with serum testosterone level of less 
than 50 ng per deciliter (1.7 nmol per liter). Eligible patients must maintain ADT; 
8. 
Could have received prior androgen blockage (bicalutamide or flutamide) but must 
have been discontinued for least 28 days; 
9. 
Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2; 
10. 
Adequate hematologic, hepatic, and renal function: 
x hemoglobin ≥ 9.0 g/dL independent of transfusions;  
x neutrophils ≥ 1.5 x 109/L;  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
10 
Approved, Date: 19 February 2018  
x platelets ≥ 100 x 109/L;  
x total bilirubin ≤ 1.5X upper limit of normal (ULN) [except for subjects with 
documented Gilbert’s disease in which case total bilirubin not to exceed 10X ULN];  
x alanine (ALT) and aspartate (AST) aminotransferase ≤ 2.5X ULN;  
x serum creatinine <1.5X ULN or calculated creatinine clearance ≥ 50 mL/min;  
x serum potassium ≥ 3.5 mM;  
x serum albumin ≥ 3.0 g/dL;  
11.  
Ability to swallow study medication tablets; 
12. 
Agrees to use a condom and another effective method of birth control if he is having 
sex with a woman of childbearing potential or agrees to use a condom if he is having 
sex with a woman who is pregnant during the treatment period and for 1 week after the 
last dose of abiraterone acetate. 
Exclusion  
1. 
Active infection or other medical condition that would make prednisone use 
contraindicated, 
2. 
Any chronic medical condition requiring a higher systemic dose of corticosteroid than 
5 mg prednisone per day, 
3. 
Pathological finding consistent with small cell carcinoma of the prostate,  
4. 
Known brain metastasis,  
5. 
Has had prior cytotoxic chemotherapy or biologic therapy for the treatment of mCRPC, 
6. 
Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer. 
The following exceptions are permitted: 
x Prior use of anti-androgens (e.g. bicalutamide) in combination with ADT (LHRH 
agonists or orchiectomy) as part of CAB; 
x Subjects may have one course of palliative radiation or surgical therapy to treat 
symptoms resulting from metastatic disease (eg, impending cord compression or 
obstructive symptoms) if it was administered at least 28 days prior to Cycle 1 Day 
1. All adverse events associated with these procedures must be resolved at least to 
Grade 1 by Cycle 1 Day 1.  
7. 
Uncontrolled hypertension (systolic blood pressure (BP) ≥160 mmHg or diastolic BP 
≥95 mmHg). Subjects with a history of hypertension are allowed provided blood 
pressure is controlled by anti-hypertensive treatment,  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
11 
Approved, Date: 19 February 2018  
8. 
Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding 
disorders secondary to hepatic dysfunction, 
9. 
History of adrenal dysfunction,  
10. 
Clinically significant heart disease as evidenced by myocardial infarction, or arterial 
thrombotic events or history of cardiac failure in the past 6 months, severe or unstable 
angina, or New York Heart Association (NYHA) Class II-IV heart disease, 
11. 
Atrial fibrillation or other cardiac arrhythmia requiring pharmacotherapy,  
12. 
Other malignancy (within 5 years), except non-melanoma skin cancer,  
13. 
Administration of an investigational therapeutic or invasive surgical procedure (not 
including surgical castration) within 28 days of Cycle 1 Day 1 or currently enrolled in 
an investigational study,  
14. 
Any condition or situation which, in the opinion of the investigator, would put the 
subject at risk, may confound study results, or interfere with the subject’s participation 
in this study.  
NOTE: Each subject will be reviewed by sponsor before enrollment to ensure that select 
eligibility criteria have been met. 
DOSAGE AND ADMINISTRATION 
Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, 
concomitantly with oral low-dose prednisone 5mg. Abiraterone acetate must be taken on an 
empty stomach. No food should be consumed for at least 2 hours before the dose of abiraterone 
acetate is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Tablets 
should be swallowed whole with water. If an abiraterone acetate dose is missed, it should be 
omitted and will not be made up. 
All subjects should remain on a stable regimen of ADT (LHRH agonists) or have had surgical 
castration. The choice of the LHRH agonist will be at the investigator's discretion and is to be 
selected prior to enrollment. Dosing (dose and frequency of administration) will be consistent 
with the prescribing information and should only be adjusted if clinically indicated to achieve 
and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM). 
EVALUATIONS  
Efficacy  
x 
Time to PSA progression is calculate from the time of enrollment to the PSA 
progression defined as ≥ 25% and ≥ 2 ng/mL after 12 weeks (in case of no decline in 
PSA from baseline), or first PSA increase that is ≥ 25% and ≥ 2 ng/mL above the nadir, 
and which is confirmed by a second value 3 or more weeks later (in case of decline of 
PSA from baseline); 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
12 
Approved, Date: 19 February 2018  
x 
PSA response rate (≥50% decline in PSA level from baseline at 12 weeks and at any 
time); 
x 
Maximal PSA post-therapy change from baseline (maximal at 12 weeks or at any time 
point PSA post-therapy change from baseline presented in waterfalls); 
x 
Overall survival (OS) (time from enrollment to death due to any cause); 
x 
Patients’ reports of pain (as measured by the average of the pain scores on the BPI-SF 
(range, 0 to 10, with higher scores indicating worse average pain). An increase in pain 
is defined as an increase in the baseline pain score at two consecutive visits by 30% or 
more, as measured by the average of the pain scores on the BPI-SF (range, 0 to 10, with 
higher scores indicating worse average pain), without a decrease in analgesic use. 
Biomarkers 
Biomarker analyses are designed to confirm previously identified markers predictive of 
response (or resistance) to abiraterone acetate or correlated with poor prognosis (e.g. low SA 
levels at baseline). Serum samples will be collected at baseline, week 12 and PSA Progression 
Visit to allow for related analyses. 
Safety  
Safety evaluations include adverse events, vital signs measurements, physical examinations, 
and clinical laboratory tests. 
ENDPOINTS 
Primary  
Time to PSA progression (PSAP) 
Secondary  
PSA response rate, Maximal PSA post-therapy change from baseline, Overall Survival (OS), 
safety and Patients’ reports of pain. 
Exploratory 
Investigate the relationship between baseline serum androgen (SA) levels (Androstenedione, 
Testosterone, dehydroepiandrosterone (DHEA), Dehydroepiandrosterone sulfate (DHEAS)) 
and PSA response and time to PSA progression. Analyze SA variability from baseline to time 
to PSAP. To collect plasma for future correlative translational research to investigate other 
serum androgens, and biomarkers that may be discovered during the study.  
STATISTICAL METHODS 
Sample Size Determination 
We assumed that the medium time to PSAP of Abiraterone plus prednisone in CRPC patients, 
which had failed to DES therapy, would be 8.5 months as in historical data with DES and 
ketoconazole1-3. A 5 months time to PSAP is the minimum effect to consider drug activity in 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
13 
Approved, Date: 19 February 2018  
this setting such as first-line chemotherapy4,5. Considering a uniform accrual over 1 year 
enrollment period, 6 months follow-up time and exponentially distributed PSAP times, a two-
sided test for the median7 with an alpha level of 0.05 and a power of 80%, 40 patients would 
need to be enrolled. In addition, considering a drop-out rate of 10%, a total sample size of 45 
patients is planned for the study.  
Efficacy Analysis  
The primary analysis population will use the efficacy population, which includes all eligible 
enrolled subjects. The efficacy population will be used for the analysis of subject disposition 
and efficacy. The safety population includes all subjects who received at least 1 dose of study 
drug. 
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A general 
description of the statistical methods to be used to analyze the efficacy and safety data is 
outlined below.  
Unless otherwise specified, all continuous endpoints will be summarized using descriptive 
statistics, which will include the number of subjects, mean, standard deviation, median, 
minimum, and maximum. All categorical endpoints will be summarized using frequencies and 
percentages. The baseline measurement will be the last value on or before the date of first study 
treatment. 
Biomarkers Analysis 
The associations of the above biomarkers with clinical response or survival endpoints will be 
assessed using appropriate statistical methods (logistic regression model or survival model), 
depending on the endpoint. 
Safety Analyses 
The safety parameters to be evaluated are the incidence, intensity, and type of adverse events, 
clinically significant changes in the subject’s physical examination findings, vital signs 
measurements, and clinical laboratory results. Exposure to study drug and reasons for 
discontinuation of study treatment will be tabulated. 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
14 
Approved, Date: 19 February 2018  
TIME AND EVENTS SCHEDULE  
 
 
Screening 
Phase 
Cycles (28 days) 
Subsequent 
cycles 
PSA progression 
visit / Early 
Withdrawal§ 
Follow-up 
Phase 
Visit no. (at the end of each cycle ± 2 days) 
1 
1§ 
1 
2 
3 
From cycle 4 
until PSA 
progression 
15-30 days after 
confirmation of PSA 
progression 
Every 3 
months, up 
to 2 years  
Day of cycle 
-28 to -1 
1 
28 
28 
28 
28 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
 
 
 
 
 
 
 
Medical history/Demographics 
X 
 
 
 
 
 
 
 
Diagnosis/extent of cancer/ Prior antineoplastic therapy 
X 
 
 
 
 
 
 
 
Vital signs (HR and blood pressure) 1 
X 
X 
X 
X 
X 
X 
X 
 
Height 
X 
 
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
X 
 
Physical examination 
X 
 
X 
X 
X 
X 
X 
 
ECOG Performance Status 
X 
X 
X 
X 
X 
X 
X 
 
ECG 
X 
 
 
 
 
 
 
 
PSA 
X 
X 
X 
X 
X2 
X 
X 
 
Hematology3 
X 
X 
X 
X 
X 
X 
X 
 
Serum Biochemistry4 
X 
X 
X 
X 
X 
X 
X 
 
Liver function5 
X 
X 
X 
X 
X 
X 
X 
 
Serum Androgens6 
 
X 
 
 
X2 
 
X 
 
BPI-SF Questionnaire7 
 
X 
 
X 
every 2 cycles 
X 
 
Prior/concomitant medications 
X 
Continuous until 30 days after last study drug dose 
Adverse events 
X 
Continuous from ICF to 30 days after last study drug dose 
Reason of discontinuation of study drug, if applicable 
 
 
 
 
 
 
X 
X 
Survival Status and subsequent therapies 
 
 
 
 
 
 
X 
X 
Blood collection for exploratory biomarkers8 
 
X 
 
 
X2 
 
X 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
15 
Approved, Date: 19 February 2018  
 
Table legend 
§ Highlight in grey - do not repeat exams and data collection if done at screening (for cycle 1) / at the end of last cycle (for PSA Progression visit) 
1. HR (heart rate) and BP (blood pressure) at screening; afterwards only blood pressure. 
2. This exam should be performed on 12 weeks from baseline. If C3D28 is delayed, perform the exam on the week 12 and do not repeat on later visit. 
3. Hemoglobin, White Blood Counts (including neutrophil), Platelet 
4. Potassium, creatinine, fasting glucose, lactate dehydrogenase, INR  
5. ALT (alanine aminotransferase), AST (aspartate aminotransferase), total bilirubin, albumin (screening only) 
6. Testosterone, Androstenedione, DHEA, DHEAS. To be collected before abiraterone and prednisone administration.  
7. BPI-SF (Brief Pain Inventory – Short Form): at cycle 1 day 1, at day 28 (+/- 2) of every 2 cycles (cycle 2, 4, 6, 8, etc.) and at PSA progression visit 
8. For subjects participating in the correlative translational study, the blood volumes will be 5 to 10 mL per study visit. Freeze and Store according “Sample Collection and 
Handling Manual”. 
 
 
 
 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
16 
Approved, Date: 19 February 2018  
ABBREVIATIONS 
 
ACTH  
adrenocorticotropic hormone 
ADT  
androgen deprivation therapy 
AE 
 
adverse event 
ALT 
 
alanine aminotransferase 
AR 
 
androgen receptor 
AST 
 
aspartate aminotransferase 
AUC  
area under the curve 
BP 
 
blood pressure 
BPI-SF 
Brief Pain Inventory - Short Form 
CAB  
complete androgen blockade  
CRPC  
castration resistant prostate cancer 
CT 
 
computerized tomography 
CYP 
 
Cytochrome 
DES   
diethylstilbestrol 
DHEA  
dehydroepiandrosterone 
DHEAS 
dehydroepiandrosterone sulfate  
DHT  
dihydrotestosterone 
ECG  
electrocardiogram 
ECOG  
Eastern Cooperative Oncology Group 
eCRF  
electronic case report form 
eDC 
 
electronic data capture 
FDA  
food and drug administration 
GCP 
 
good clinical practice 
GnRH  
Gonadotropin-releasing hormone 
HR 
 
hazard ratio 
ICF 
 
informed consent form 
ICH 
 
International Conference on Harmonisation 
IEC 
 
Independent Ethics Committee 
IDMC  
independent data monitoring committee 
IRB 
 
Institutional Review Board 
ITT 
 
intention-to-treat 
LHRH  
luteinizing hormone-releasing hormone 
mCRPC 
metastatic castration-resistant prostate cancer  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
17 
Approved, Date: 19 February 2018  
MedDRA 
Medical Dictionary for Regulatory Activities 
MRI 
 
magnetic resonance imaging 
mRNA  
messenger ribonucleic acid 
NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events 
NYHA  
New York Heart Association 
OS 
 
overall survival 
PCWG2 
Prostate Cancer Clinical Trials Working Group 
PQC 
 
Product Quality Compliant 
PSA 
 
prostate-specific antigen 
PSAP   
prostate-specific antigen progression 
QD 
 
once a day (quaque die) 
RECIST 
response evaluation criteria in solid tumors 
rPFS  
radiographic progression free survival 
SA 
 
serum androgen 
SAE 
 
serious adverse event 
SD 
 
stable disease 
ULN  
upper limit of normal 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
18 
Approved, Date: 19 February 2018  
1. 
INTRODUCTION 
1.1. 
Background  
1.1.1. 
The Rationale for Abiraterone Acetate in the Management of 
Castration-Resistant Prostate Cancer (CRPC) 
Testosterone production is a key element in the control of prostate cancer growth. In the testis 
and adrenals, C17,20-lyase converts the C21 precursors to the corresponding C19 androgens. 
Testosterone, a C19 androgen, is further converted to the more potent androgen 
dihydrotestosterone (DHT) by 5α-reductase in the prostate6,7. Both testosterone and DHT 
stimulate prostatic growth, although DHT plays a much more important role than testosterone 
in the organogenesis and homeostasis of the prostate. Inhibitors of the enzyme 17α 
hydroxylase/C17,20- lyase, such as abiraterone acetate and abiraterone, block testosterone 
production both in the testis and adrenal gland. Standard androgen deprivation therapies, such 
as orchiectomy and treatment with gonadotropin-releasing hormone (GnRH) analogues, ablate 
androgen production by the testis but do not affect androgen production by the adrenals, which 
continue to supply androgens to the prostate cancer and, thereby, promote disease progression8. 
In castrated men, as much as 10% of baseline circulating testosterone remains because of 
conversion of adrenal androgens to testosterone9. In addition, more than 10% of baseline 
concentrations of the androgens testosterone, DHT, dehydroepiandrosterone sulfate (DHEAS), 
and androstenedione remain in recurrent prostate cancer tissue after castration10. Autocrine 
synthesis may contribute to these high prostate tumor androgen concentrations since high 
concentrations of CYP17 messenger ribonucleic acid (mRNA) are found in high Gleason score 
prostate tumors of subjects who experience metastasis. Furthermore, the androgen receptor 
(AR) becomes amplified in prostate tumor cells, and the amplified AR is activated by extremely 
low androgen concentrations11. The sensitivity of the AR is also increased by the 
overexpression of 2 nuclear coactivators, which enhances activation of the AR at lower 
testosterone concentrations12,13. Together, the increased sensitivity of AR with persistent 
androgens after castration results in tumor progression in many men with CRPC. Therefore, 
even though the progression of prostate cancer may be slowed in the absence of testicular 
androgens, the tumor remains responsive to stimulation from extratesticular or autocrine 
androgens. Because of this responsiveness, anti-androgen therapy with abiraterone acetate may 
still be effective after medical or surgical castration. The term hormone refractory prostate 
cancer should now be replaced with the more accurate name, CRPC, to reflect the continued 
sensitivity of men after castration to ultra low level androgen deprivation by abiraterone 
acetate. Current second-line hormone therapies include anti-androgens such as flutamide, 
bicalutamide, and nilutamide, estrogens including diethylstilbestrol, or adrenal androgen 
synthesis inhibitors such as hydrocortisone alone, ketoconazole, and aminoglutethimide14. The 
adverse events (AEs) observed in subjects receiving ketoconazole or aminoglutethimide were 
thought to be related to the nonspecific nature of enzyme inhibition. Since abiraterone acetate, 
and its chief metabolite abiraterone, is selective inhibitors of 17α hydroxylase/C17,20-lyase, 
administration is expected to reduce the risk of nonspecific enzyme inhibition affecting the 
synthesis of glucocorticoids and mineralocorticoids, improving efficacy and minimizing AEs.  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
19 
Approved, Date: 19 February 2018  
1.1.2. 
Abiraterone Acetate 
ZYTIGA® (abiraterone acetate) is a prodrug of abiraterone, an irreversible inhibitor of 17α 
hydroxylase/C17,20-lyase (cytochrome P450c17 [CYP17]), a key enzyme required for 
testosterone synthesis. This enzyme is found in the testis, adrenals, and prostate tumors15-17. 
Marketing authorization for ZYTIGA and prednisone/prednisolone was granted in April 2011 
in the United States and in September 2011 in the European Union. Treatment with ZYTIGA 
improves survival in patients with metastatic castration-resistant prostate cancer. 
For the most comprehensive nonclinical and clinical information regarding the efficacy and 
safety of abiraterone acetate, refer to the latest version of the Investigator's Brochure for 
abiraterone acetate. The term sponsor used throughout this document refers to the entities listed 
in the Contact Information page(s), which will be provided as a separate document. 
1.1.3. 
Clinical Experience with Abiraterone Acetate 
In healthy subjects after single dose administration of 1,000 mg abiraterone acetate, there is a 
substantial food effect and absorption of abiraterone acetate increases greatly with increasing 
fat content of a meal (Study COU-AA-009)18. Compared to administration after an overnight 
fast, geometric mean maximum concentration (Cmax) and the area under the concentration-
time curve (AUC) of abiraterone increased approximately 7-fold and 5-fold, respectively, when 
administered following a low-fat meal (estimated 2% of calories from fat) and increased by 
approximately 17-fold and 10-fold, respectively, when administered following a high-fat meal 
(estimated 56% of calories from fat).  
In the two large phase 3 randomized studies (COU-AA-301 and COU-AA-302), treatment with 
abiraterone acetate and prednisone had an acceptable safety profile and resulted in a favorable 
benefit/risk ratio. The safety profile of abiraterone acetate plus prednisone was distinct from 
that of cytotoxic agents. Adverse events usually did not interfere with administration of 
abiraterone acetate. In the combined dataset of safety for studies COU-AA-301 and COU-AA-
302, the most frequently reported adverse events were fatigue (43.8%), back pain (32.6%), 
nausea (28.4%), arthralgia (29.5%), constipation (26.1%), bone pain (24.2%), peripheral 
edema (26.0%), hot flush (20.6%) and diarrhea (20.5%). Most events were Grade 1 or 2 in 
severity. Abiraterone acetate may cause hypertension, hypokalemia, and fluid retention as a 
consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Co-
administration of a corticosteroid suppresses adrenocorticotropic hormone (ACTH) drive 
resulting in a reduction in incidence and severity of these adverse reactions. Caution is required 
in treating patients whose underlying medical conditions might be compromised by increases 
in blood pressure, hypokalemia (eg, those on cardiac glycosides), or fluid retention (eg, those 
with heart failure), severe or unstable angina pectoris, recent myocardial infarction or 
ventricular arrhythmia, and those with severe renal impairment. 
Study COU-AA-301 was a Phase 3, multinational, randomized, double-blind, placebo-
controlled study of oral abiraterone acetate and oral prednisone in 1,195 subjects with mCRPC 
whose disease had progressed on or after 1 or 2 chemotherapy regimens, at least one of which 
contained docetaxel. The study conclusively demonstrated that further lowering testosterone 
concentrations below those achieved with standard therapy to suppress androgen production 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
20 
Approved, Date: 19 February 2018  
(LHRH agonists or orchiectomy) using CYP17 inhibition with abiraterone acetate improves 
survival in patients with mCRPC19. 
1.1.4. 
Clinical Experience with Abiraterone Acetate in CRPC chemo-
naïve patients 
Study COU-AA-302 was a Phase 3, multinational, randomized, double-blind, placebo-
controlled study of abiraterone acetate and oral prednisone in 1,088 asymptomatic or mildly 
symptomatic subjects with mCRPC who had not received chemotherapy20 This study had co-
primary endpoints of radiographic progression free survival (rPFS) and overall survival. 
Treatment with abiraterone acetate plus prednisone decreased the risk of radiographic 
progression or death by 57% compared with placebo plus prednisone (HR=0.425; p<0.0001). 
The study met its nominal significance level (0.01) for the co-primary endpoint of rPFS by 
independent review. There was a 25% decrease in the risk of death in the abiraterone acetate 
and prednisone group compared with the placebo plus prednisone group (HR=0.752; 
p=0.0097) when the Independent Data Monitoring Committee (IDMC) unanimously 
recommended unblinding the treatment and allowing subjects in the placebo group to receive 
abiraterone acetate. The median OS had not been reached for the abiraterone acetate group and 
was 27.2 months in the placebo group. The safety profile was similar, although the duration of 
treatment was longer, to that observed with abiraterone acetate plus prednisone in subjects in 
the post-docetaxel setting (COU-AA-301). 
1.2. 
Overall Rationale for the Study 
Although advanced prostate cancer is initially sensitive to androgen deprivation, most patients 
invariably develop progressive disease, and most deaths occur after the cancer has progressed 
to castration-resistant status. Historically, second-line hormonal therapy after maximum 
androgen blockade (e.g. diethylstilbestrol (DES), ketoconazole, steroids) has demonstrated 
clinical benefit among patients with chemo-naïve castration-resistant prostate cancer. Despite 
of secondary hormonal therapy being used in clinical practice, none of these drugs are approved 
by regulatory agencies in this indication and do not show survival benefit.  
Abiraterone was recently approved as for metastatic castration-resistant prostate cancer 
patients who had not received cytotoxic chemotherapy. In the pivotal study COU-AA-302, 
patients with visceral metastatic disease and prior treatment with subsequent hormonal therapy 
lines were excluded. A preliminary data from a phase 2 ongoing study showed that a substantial 
number of patients with prior ketoconazole exposure respond to Abiraterone indicative of the 
greater CYP 17 inhibition induced by Abiraterone and retained CYP 17 dependence in 
mCRPC. The lower responses observed in this study compared to keto naïve mCRPC suggests 
the potential for overlapping mechanisms of resistance to Abiraterone and ketoconazole21. In a 
retrospective study, patients with mCRPC, chemo-naïve and that failed to DES, the treatment 
with, abiraterone resulted in ≥ 50% PSA declines in 20/27 (74.1%) and 8.5 months median 
time to PSA progression. This study suggests that Abiraterone has significant antitumour 
activity in men with mCRPC even after DES exposure3. 
Thus, Abiraterone has not been well investigated in patients with prostate cancer progressing 
on secondary hormone therapy (especially DES) and that strategy could delay the start of 
chemotherapy. In addition, the evaluation of SA as a predictor of treatment benefit with 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
21 
Approved, Date: 19 February 2018  
Abiraterone after DES exposure was not yet described. This phase II trial studies the efficacy 
of Abiraterone in patients with metastatic hormone-resistant prostate cancer that have 
progressed to DES therapy.  
2. 
OBJECTIVE AND HYPOTHESIS 
2.1. 
Objectives 
Primary Objective 
The primary objective is to evaluate the efficacy, based on Prostate-specific antigen (PSA) 
progression, of Abiraterone acetate in patients with metastatic castration-resistant prostate 
cancer (mCRPC), chemo-naive, who received a prior Diethylstilbestrol Therapy (DES). 
Secondary Objective 
The secondary objectives are to evaluate the clinically relevant Prostate-specific antigen (PSA) 
and survival improvements, safety of abiraterone acetate plus low-dose prednisone, as well as 
to explore the relationship between serum androgen levels and response to therapy. 
2.2. 
Hypothesis 
Abiraterone acetate could be clinically effective and delay the start to chemotherapy in mCRPC 
patients who have progressed on DES therapy. 
3. 
STUDY DESIGN AND RATIONALE 
3.1. 
Overview of Study Design 
This is a phase II, multinational, multicenter, open-label, single arm study to determine if 
mCRPC patients who failed to prior DES therapy will benefit from the addition of abiraterone 
acetate and low-dose prednisone to androgen deprivation therapy (ADT). In this study, ADT 
refers specifically to luteinizing hormone releasing hormone (LHRH) agonists or orchiectomy. 
Approximately 45 subjects will be enrolled. Subjects must have metastatic disease as 
documented by positive bone scan or metastatic lesions on CT or MRI to be eligible. Need to 
have PSA progression according to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) 
criteria22 or radiographic progression per RECIST version 1.1. Eligible subjects must maintain 
ADT, with serum testosterone level of less than 50 ng per deciliter (1.7 nmol per liter) and 
Eastern Cooperative Oncology Group (ECOG) performance status grade 0, 1 or 2. Selection of 
the LHRH agonist is by Investigator’s choice provided that the dosing (dose and frequency of 
administration) is consistent with prescribing information. Abiraterone acetate and low-dose 
prednisone will be considered as study drugs. 
The study will consist of a Screening Phase of up to 28 days before enrollment to establish 
study eligibility and document baseline measurements; a PSA Evaluation Phase; and a Follow-
up Phase of up to 24 months to monitor survival status and subsequent prostate cancer therapy. 
Each cycle of abiraterone therapy is 28 days. Treatment will continue until PSA progression, 
clinical progression, consent withdrawal, occurrence of unacceptable toxicity or study 
termination. Patients experiencing PSA progression might be offered continuation on 
abiraterone treatment at the discretion of the investigator. Subjects who meet all of the inclusion 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
22 
Approved, Date: 19 February 2018  
criteria and none of the exclusion criteria will be enrolled to receive abiraterone acetate [1,000 
mg once daily] plus low-dose prednisone [5 mg once daily]. Patients need to be under ADT 
[LHRH agonist or orchiectomy] as per discretion of attending physician. 
Serum samples collected at multiple time points during the study. Other samples could be 
obtained from subjects for biomarker evaluations. 
Subjects will be monitored for safety throughout the study. Adverse events including laboratory 
adverse events will be graded and summarized using National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0. Dose modification will 
be made as required according to dose modification rule.  
A study flowchart is provided in Figure 1. 
 
Figure 1 – Study Flowchart 1 
 
ADT: androgen deprivation therapy (LHRH agonist or orchiectomy; DES: Diethylstilbestrol; 
EOS: end of study; QD: once a day 
 
4. 
SUBJECT POPULATION  
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following 2 subsections. 
4.1. 
Inclusion Criteria 
Each potential subject must satisfy all of the following criteria to be enrolled in the study: 
1. 
Willing and able to provide written informed consent;  
Screening Phase
(Day -28 to Day -1)
- Metastatic CRPC
- Under ADT and testosterone level < 50 ng/dL (1.7 nmol/L)
- Failure to DES therapy by PSA progression (PCWG2) or RECIST v. 1.1
Study Visits
(28-day cycles until PSA progression)
Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD + ADT
Follow Up Phase
(every 3 months for up to 24 months or EOS)
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
23 
Approved, Date: 19 February 2018  
2. 
Men age 18 years and older;  
3. 
Histologically or cytologically confirmed adenocarcinoma of the prostate without 
neuroendocrine differentiation or small cell histology; 
4. 
Prior therapy with DES for castration resistant prostate cancer. Patients should 
demonstrate evidence of progression (see below definitions) on DES or evidence of 
grades 3/4 toxicities on DES;  
5. 
Progressive disease: PSA progression per PCWG2 criteria (sequence of rising PSA 
values at least 1 week apart and minimum PSA level of 2 ng/mL) or radiographic 
progression per RECIST (version 1.1); 
6. 
Metastatic disease documented by positive bone scan or metastatic lesions on CT or 
MRI; 
7. 
Ongoing ADT (LHRH agonist or orchiectomy), with serum testosterone level of less 
than 50 ng per deciliter (1.7 nmol per liter). Eligible patients must maintain ADT; 
8. 
Could have received prior androgen blockage (bicalutamide or flutamide) but must 
have been discontinued for at least 28 days; 
9. 
Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2 
(Attachment 2); 
10. 
Adequate hematologic, hepatic, and renal function: 
x hemoglobin ≥ 9.0 g/dL independent of transfusions;  
x neutrophils ≥ 1.5 x 109/L;  
x platelets ≥ 100 x 109/L;  
x total bilirubin ≤ 1.5X upper limit of normal (ULN) [except for subjects with 
documented Gilbert’s disease in which case total bilirubin not to exceed 10X ULN];  
x alanine (ALT) and aspartate (AST) aminotransferase ≤ 2.5X ULN;  
x serum creatinine <1.5X ULN or calculated creatinine clearance ≥ 50 mL/min;  
x serum potassium ≥ 3.5 mM;  
x serum albumin ≥ 3.0 g/dL;  
11. 
Ability to swallow study medication tablets;  
12. 
Agrees to use a condom and another effective method of birth control if he is having 
sex with a woman of childbearing potential or agrees to use a condom if he is having 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
24 
Approved, Date: 19 February 2018  
sex with a woman who is pregnant during the treatment period and for 1 week after the 
last dose of abiraterone acetate. 
4.2. 
Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from participating in the 
study: 
1. 
 Active infection or other medical condition that would make prednisone use 
contraindicated;  
2. 
 Any chronic medical condition requiring a higher systemic dose of corticosteroid than 
5 mg prednisone per day;  
3. 
 Pathological finding consistent with small cell carcinoma of the prostate;  
4. 
 Known brain metastasis;  
5. 
 Has had prior cytotoxic chemotherapy or biologic therapy for the treatment of mCRPC;  
6. 
Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate 
cancer; The following exceptions are permitted: 
x Prior use of anti-androgens (e.g. bicalutamide) in combination with ADT (LHRH 
agonists or orchiectomy) as part of CAB; 
x Subjects may have one course of palliative radiation or surgical therapy to treat 
symptoms resulting from metastatic disease (e.g., impending cord compression or 
obstructive symptoms) if it was administered at least 28 days prior to Cycle 1 Day 
1. All 
adverse events associated with these procedures must be resolved at 
least to Grade 1 by Cycle 1 Day 1;  
7. 
Uncontrolled hypertension (systolic blood pressure (BP) ≥160 mmHg or diastolic BP 
≥95 mmHg). Subjects with a history of hypertension are allowed provided blood 
pressure is controlled by anti-hypertensive treatment;  
8. 
Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding 
disorders secondary to hepatic dysfunction; 
9. 
History of adrenal dysfunction;  
10. 
Clinically significant heart disease as evidenced by myocardial infarction, or arterial 
thrombotic events or history of cardiac failure in the past 6 months, severe or unstable 
angina, or New York Heart Association (NYHA) Class II-IV heart disease (Attachment 
3); 
11. 
Atrial fibrillation or other cardiac arrhythmia requiring pharmacotherapy;  
12. 
Other malignancy (within 5 years), except non-melanoma skin cancer;  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
25 
Approved, Date: 19 February 2018  
13. 
Administration of an investigational therapeutic or invasive surgical procedure (not 
including surgical castration) within 28 days of Cycle 1 Day 1 or currently enrolled in 
an investigational study;  
14. 
Any condition or situation which, in the opinion of the investigator, would put the 
subject at risk, may confound study results, or interfere with the subject’s participation 
in this study.  
NOTE: Each subject will be reviewed by sponsor before enrollment to ensure that select 
eligibility criteria have been met. 
5. 
DOSAGE AND ADMINISTRATION 
5.1. 
Planned Dose 
Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, 
concomitantly with oral low-dose prednisone 5mg. Abiraterone must be taken on an empty 
stomach. No food should be consumed for at least 2 hours before the dose of abiraterone acetate 
is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Tablets should be 
swallowed whole with water. If an abiraterone dose is missed, it should be omitted and will not 
be made up. 
All subjects should remain on a stable regimen of ADT (LHRH agonists) or have had surgical 
castration i.e. orchiectomy. The choice of the LHRH agonist will be at the Investigator's 
discretion and is to be selected prior to enrollment. Dosing (dose and frequency of 
administration) will be consistent with the prescribing information and should only be adjusted 
if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 
ng/dL or 1.7 nM). 
In case of early study termination, any patients still receiving study drug will continue to do 
so, if the physician considers beneficial to the patient, under a Continued Access Program, 
following the applicable regulations. Investigators will be trained on Janssen and regulatory 
pharmacovigilance requirements and patients will be followed for safety until 30 days after the 
last study drug dose. 
5.2. 
Dose Modification and Management of Toxicity 
In clinical studies in subjects with mCRPC, the most common adverse events related to 
abiraterone acetate have included fatigue most likely attributable to the underlying disease; and 
hypertension, hypokalemia, fluid retention/edema, and due to mineralocorticoid excess caused 
by compensatory ACTH drive. In this study, low-dose prednisone is expected to mitigate these 
effects through abrogation of the ACTH drive (see Section 5.4). 
Following prolonged therapy with corticosteroids, subjects may develop Cushings syndrome 
characterized by central adiposity, thin skin, easy bruising, and proximal myopathy. 
Withdrawal of the corticosteroid may result in symptoms that include fever, myalgia, fatigue, 
arthralgia, and malaise. This may occur even without evidence of adrenal insufficiency. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
26 
Approved, Date: 19 February 2018  
In the event where dose-reduction is used for adverse event management, 2 dose 
reductions are allowed. At each dose reduction, 1 tablet of abiraterone acetate will be 
removed, e.g., 4→3 tablets, and 3→2 tablets. Any return to protocol dose level (4 tablets) after 
dose reduction must follow documentation of adverse event resolution and a discussion with 
the sponsor. 
In case of adverse events, the next cycle can be withheld for a maximum of 4 weeks until 
AE resolution (grade ≤1). If AE is not resolved and study treatment not started during this 
period, the patient needs to be discontinued from the study. 
5.3. 
Guidelines for Abnormal Liver Function Test 
For subjects who develop liver function test abnormalities (ALT and/or AST greater than 5 X 
ULN but not exceeding 20 X ULN or total bilirubin greater than 3 X ULN but not exceeding 
10X ULN), study drug should be interrupted. Treatment may be restarted at a reduced dose of 
750 mg (3 tablets) once daily following return of liver function tests to the subject's baseline 
or to AST and ALT less than or equal to 2.5 X ULN and total bilirubin less than or equal to 1.5 
X ULN. 
For subjects with ALT and/or AST greater than 20 X ULN or total bilirubin greater than 10 X 
ULN, study drug should be interrupted. The decision to restart treatment at a reduced dose will 
be made in consultation with the sponsor medical monitor on an individual basis. 
For subjects who resume treatment, serum transaminases and bilirubin should be monitored at 
a minimum of every 2 weeks for 3 months and monthly thereafter. 
If liver function test abnormality recurs at the dose of 750 mg (3 tablets) once daily, re-
treatment may be restarted at a reduced dose of 500 mg (2 tablets) once daily following return 
of liver function tests to the subject's baseline or to AST and ALT less than or equal to 2.5X 
ULN and total bilirubin less than or equal to 1.5X ULN. 
If liver function test abnormality recurs at the reduced dose of 500 mg (2 tablets) once daily, 
study drug should be discontinued. 
5.4. 
Guidelines for Hypertension, Hypokalemia and Fluid Retention/Edema 
Due to Mineralocorticoid Excess 
The study drug should be used with caution in subjects with a history of cardiovascular disease. 
The study drug may cause hypertension, hypokalemia, and fluid retention as a consequence of 
increased mineralocorticoid levels resulting from CYP17 inhibition. Caution should be 
exercised when treating subjects whose underlying medical conditions might be compromised 
by increases in blood pressure, hypokalemia, or fluid retention. 
In patients with pre-existing hypokalemia or those who develop hypokalemia on study 
treatment, consider maintaining the subject’s potassium level at 4.0 mM or higher. If 
hypokalemia persists despite optimal potassium supplementation and adequate oral intake, or 
if any of the other mineralocorticoid effects persist, the dose of prednisone may be increased 
to 10 mg/day and documented in the study medication eCRF. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
27 
Approved, Date: 19 February 2018  
For subjects who develop drug-related Grade 3 or higher toxicities including hypertension, 
hypokalemia, edema, and other non-mineralocorticoid toxicities, treatment should be withheld 
and appropriate medical management should be instituted. Treatment with abiraterone acetate 
should not be reinitiated until symptoms of the toxicity have resolved to Grade 1 or baseline. 
In the event where dose reduction is used for adverse event management, please refer to Section 
5.2. 
6. 
TREATMENT COMPLIANCE 
Accurate records of all drug shipments as well as tablets dispensed and returned will be 
maintained. This inventory must be available for inspection by designated sponsor or 
regulatory authority representatives at any time. Drug supplies are to be used only in 
accordance with this protocol and under the supervision of the investigator. Study drug 
administration and dosing compliance will be assessed at each study visit, starting with Cycle 
2. A count of all study drug provided by the sponsor will be conducted during the study.  
If dosing compliance is not 100% in the absence of toxicity, then subjects should be re-
instructed regarding proper dosing procedures and may continue with the study. Subsequent 
dosing compliance procedure will be conducted at each study visit. If the number of study drug 
doses taken by the subject is 75% in the absence of toxicity or disease progression, then subjects 
should be re-instructed regarding proper dosing procedures. Subjects who have study drug 
dosing compliance of 75% for 2 consecutive cycles should be discontinued from the study. 
The study site must maintain accurate records demonstrating dates and amount of study drug 
received, to whom dispensed (subject by subject accounting), and accounts of any study drug 
accidentally or deliberately destroyed. At the end of the study, reconciliation must be made 
between the amount of study drug supplied, dispensed, and subsequently destroyed or returned 
to sponsor or its representative. 
7. 
PRESTUDY AND CONCOMITANT THERAPY 
All pre-study therapies administered up to 28 days before first dose of study drug must be 
recorded at screening. All concomitant therapies must be recorded on the subject’s eCRF 
throughout the study beginning when the first dose of study drug is administered. 
Concurrent enrollment in another investigational drug or device study is prohibited. The 
sponsor must be notified in advance (or as soon as possible thereafter) of any instances in which 
prohibited therapies are administered. 
All therapies (prescriptions or over-the-counter medications, including vitamins and herbal 
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, special 
diets, exercise regimens) different from study drug must be recorded in the concomitant therapy 
section of the eCRF. 
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
28 
Approved, Date: 19 February 2018  
7.1. 
Permitted Supportive Care and Interventions 
x Use of as needed opioid analgesics for cancer-related pain  
x Bisphosphonates and denosumab for management of bone-related metastasis according to 
their market authorized approved label  
x LHRH agonists to maintain testosterone <50 ng/dL or <1.7 nM (for those subjects who do 
not have orchiectomy)  
x Conventional multivitamins, selenium and soy supplements  
x Prednisone dose increase up 10 mg/day is permitted to manage refractory mineralocorticoid 
related toxicities  
x Additional systemic glucocorticoid administration such as “stress dose” glucocorticoid is 
permitted when clinically indicated for a life threatening medical condition, and in such 
cases, the use of steroids will be documented as concomitant drug  
x Transfusions and hematopoietic growth factors per institutional practice guidelines  
x If the permissibility of a specific drug/treatment is in question, then please contact the study 
sponsor 
x Radiotherapy 
7.2. 
Special Concomitant Therapy 
The following concomitant therapies warrant special attention: 
Caution is advised when abiraterone acetate is administered with medicinal products activated 
by or metabolized by CYP2D6, particularly with medicinal products that have a narrow 
therapeutic index. Dose reduction of medicinal products with a narrow therapeutic index that 
are metabolized by CYP2D6 should be considered. Examples of medicinal products 
metabolized by CYP2D6 include metoprolol, propranolol, desipramine, venlafaxine, 
haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone and tramadol (the latter 
3 products requiring CYP2D6 to form their active analgesic metabolites). 
Based on in vitro data, abiraterone acetate is an inhibitor of the hepatic drug-metabolizing 
enzyme, CYP2C8. Examples of medicinal products metabolized by CYP2C8 include paclitaxel 
and repaglinide. There are no clinical data on the use of abiraterone acetate with drugs that are 
substrates of CYP2C8.  
Based on in vitro data, abiraterone is a substrate of CYP3A4. The effects of strong CYP3A4 
inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, 
telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) or inducers (eg, phenytoin, 
carbamazepine, rifampicin, rifabutin, phenobarbital) on the pharmacokinetics of abiraterone 
have not been evaluated, in vivo. Strong inhibitors and inducers of CYP3A4 during treatment 
are to be avoided, or used with caution. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
29 
Approved, Date: 19 February 2018  
For more information see Attachment 4. 
7.3. 
Prohibited Medications  
x Investigational agents other than abiraterone acetate  
x Other antineoplastic agents  
x 5-α-reductase inhibitors  
x Chemotherapy  
x Immunotherapy  
x Anti-androgens (e.g., bicalutamide, nilutamide, flutamide, cyproterone acetate) except in 
situations as outlined for management of tumor flare anticipated with the initiation of 
continuous LHRH agonist  
x Systemic ketoconazole (or other azole drugs such as fluconazole or itraconazole)  
x Diethylstilbestrol (DES) or similar  
x Other preparations such as saw palmetto thought to have endocrine effects on prostate 
cancer 
x Radiopharmaceuticals such as strontium (89Sr) or samarium (153Sm) or similar analogues 
such as radium-223 
x Spironolactone 
x Digoxin, digitoxin, and other digitalis drugs, Fludrocortisone acetate (Florinef) 
8. 
STUDY EVALUATIONS 
8.1. 
Study Procedures 
8.1.1. 
Overview 
The Time and Events Schedule included in the Synopsis summarizes the frequency and timing 
of efficacy, and safety assessments. All visit-specific PRO assessments during a visit should 
be conducted before any tests, procedures, or other consultations for that visit to prevent 
influencing subject perceptions. 
8.1.2. 
Screening Phase 
A signed informed consent must be obtained before any study-specific assessments are 
performed. Informed consent may be obtained up to 28 days before the first dose of study drug. 
Screening procedures to evaluate subject eligibility for the study will be conducted within 28 
days prior to Cycle 1 Day 1. 
Once select eligibility criteria are confirmed, subjects will be enrolled to the study.  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
30 
Approved, Date: 19 February 2018  
8.1.3. 
Study Visits 
Subjects must start taking study drug within 7 days from the study enrollment. The treatment 
begins on Cycle 1 Day 1 and continues until PSA progression, clinical progression, consent 
withdrawal, or the occurrence of unacceptable toxicity.  
Study visits for each cycle will have a 2 day window. Study visits will be calculated from the 
Cycle 1 Day 1 date and continues until PSA Progression Visit. Subjects may have imaging 
performed at any time as per discretion of Investigator, but image assessments are not part of 
this protocol.  
Investigators will review all clinical, laboratory and imaging data, and will use this information 
to make decisions about dose modification and study medication discontinuation. PSA results 
from every other cycle starting with Cycle 2 will be available to the investigators. Investigators 
will need to notify if testosterone results do not fall below the definition of castration 
concentrations (<50 ng/dL or <1.7 nM). 
8.1.4. 
PSA Progression/Early Withdrawal 
The PSA Progression Visit should be scheduled between 15 to 30 days after confirmation of 
PSA progression to collect protocol endpoints. 
There is an expected data collection period of up to 24 months per patient after enrollment to 
monitor survival status and, if applicable, subsequent prostate cancer therapy. 
8.1.5. 
Post-PSA Progression (Follow-Up) 
After PSA progression, subject status will be monitored every 3 months for up to 24 months (2 
years) or until subject death, lost to follow-up, withdrawal of consent, or study termination. 
Information regarding survival status and initiation of subsequent prostate cancer therapies will 
be collected. If patient is using abiraterone acetate, adverse events and concomitant medication 
should be followed. Visits to the clinic are not required; sites may collect the information by 
telephone interview, chart review, or other convenient methods. If the follow-up information 
is obtained via telephone contact, then written documentation of the communication must be 
available for review in the source documents. 
In case of early study termination, any patients still receiving study drug will continue to do 
so, if the physician considers beneficial to the patient, under a Continued Access Program, 
following the applicable regulations. Investigators will be trained on Janssen and regulatory 
pharmacovigilance requirements and patients will be followed for safety until 30 days after the 
last study drug dose. 
8.2. 
Efficacy 
8.2.1. 
Evaluations 
Considering that image assessment is not part of this protocol, tumor assessment if performed 
as per institution standard of care or in case of signs or symptoms suggestive of disease 
progression, including escalating pain not referable to another cause, worsening ECOG 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
31 
Approved, Date: 19 February 2018  
performance status grade, or physical examination findings consistent with disease 
progression, will be recorded.  
8.2.2. 
Endpoints  
8.2.2.1. 
Primary Endpoint 
The primary endpoint is time to PSA progression (PSAP) defined as the date from enrollment 
to the date of first PSA progression (as per PCWG2)22 . 
- PSA progression (PCWG2) is defined as ≥ 25% and ≥ 2 ng/mL after 12 weeks (in case of no 
decline in PSA from baseline), or first PSA increase that is ≥ 25% and ≥ 2 ng/mL above the 
nadir, and which is confirmed by a second value 3 or more weeks later (in case of decline of 
PSA from baseline). 
8.2.2.2. 
Secondary Endpoints 
- PSA response rate (≥50% decline in PSA level from baseline at 12 weeks and at any time). 
- Maximal PSA post-therapy change from baseline (maximal at 12 weeks or at any time point 
PSA post-therapy change from baseline presented in waterfalls). 
- Overall survival (OS) (time from enrollment to death due to any cause). 
- Patients’ reports of pain (as measured by the average of the pain scores on the BPI-SF (range, 
0 to 10, with higher scores indicating worse average pain). An increase in pain is defined as an 
increase in the baseline pain score at two consecutive visits by 30% or more, as measured by 
the average of the pain scores on the BPI-SF (range, 0 to 10, with higher scores indicating 
worse average pain), without a decrease in analgesic use. 
Exploratory:  
To investigate the association between SA levels (Androstenedione, Testosterone, DHEA, 
DHEAS) and PSA response and time to PSAP. Analyze SA variability from baseline to time 
to PSAP.  
Furthermore serum samples (plasma) will be collected and stored at the time points (baseline, 
week 12 and PSA Progression) indicated in the Time and Events Schedule table for potential 
correlative translational research projects such as other serum androgens, and others 
biomarkers that may be discovered during the study. Biomarker analyses are dependent upon 
the availability of appropriate biomarker assays and may be deferred or not performed, if during 
or at the end of the study, it becomes clear that the analysis will have no scientific value, or 
there are not enough samples or not enough responders to allow for adequate biomarker 
evaluation.  
8.2.2.3. 
Brief Pain Inventory-Short Form (BPI-SF) 
Pain will be evaluated using the BPI-SF instrument. A sample of the BPI-SF questionnaire 
along with detailed instructions will be provided to the sites in a separate appendix. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
32 
Approved, Date: 19 February 2018  
8.3. 
Safety Evaluations 
The evaluation period for safety will start at the time a signed and dated informed consent form 
is obtained to at least 30 days after the last dose of study drug or recovery from all acute 
toxicities associated with the study drug administration. Adverse events will be reported by the 
subject for the duration of the study. Adverse events including laboratory adverse events will 
be graded and summarized according to the NCI-CTCAE, Version 4.0. 
Any clinically significant abnormalities persisting at the end of the study or during early 
withdrawal will be followed by the investigator until resolution or until a clinically stable 
endpoint is reached. The study will include the following evaluations of safety according to the 
time points provided in the Time and Events Schedule. 
Adverse Events 
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, 
or the subject's legally-acceptable representative). Adverse events will be followed by the 
investigator as specified in Section 11 Adverse Event Reporting. 
Clinical Laboratory Tests 
All laboratory tests will be performed by local laboratory. Blood samples for serum chemistry 
and hematology will be collected. The following tests will be performed: 
Hematology Panel 
Serum Biochemistry Panel 
Liver Function Tests 
- hemoglobin  
- platelet count  
- white blood cells 
including neutrophil count  
- potassium 
- creatinine 
- fasting glucose  
- lactate dehydrogenase 
- INR 
- alanine 
aminotransferase 
(ALT/SGPT) 
- aspartate aminotransferase 
(AST/SGOT) 
- total bilirubin 
- albumin (Screening only) 
 
In addition, testosterone, androstenedione, DHEA, DHEAS and PSA will be evaluated 
periodically throughout the study. PSA results from every other cycle starting with Cycle 2 will 
be available to the investigators. Investigators will need to notify if testosterone results do not 
fall below the definition of castration concentrations (<50 ng/dL or <1.7 nM). 
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the adverse event section of the eCRF. 
Electrocardiogram 
Electrocardiograms (ECGs) (12-lead) will be recorded at screening. Computer-generated 
interpretations of ECGs should be reviewed for data integrity and reasonableness by the 
investigator. If blood sampling or vital sign measurement is scheduled at the same visit as ECG 
recording, then it is recommended that the procedures should be performed in the following 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
33 
Approved, Date: 19 February 2018  
order: ECG(s), vital signs, blood draw. ECGs should not be obtained when serum potassium is 
<3.5 mM/L. Hypokalemia should be corrected prior to ECG collection. 
Vital Signs 
Heart rate and blood pressure will be measured at Screening. At all subsequent study visits, 
including the PSA Progression Visit, only blood pressure will be measured. 
Physical Examination 
Physical examinations will be directed at detecting adverse events and should be completed as 
specified in the Time and Events Schedule. Physical examinations should be performed by the 
same evaluator throughout the study, whenever possible. Subject height will be measured at 
screening only. Weight will be measured at Screening and Study visits until PSA Progression 
Visit. Physical examination includes head, eyes, ears, nose and throat, chest, cardiac, 
abdominal, extremities, neurologic, and lymph node examinations. Any clinically significant 
change in physical findings noted during the study should be reported as an adverse event. Any 
clinically significant abnormalities persisting at the end of the study will be followed by the 
investigator until resolution or until reaching a clinically stable endpoint. 
8.4. 
Sample Collection and Handling 
The actual dates of sample collection must be recorded in the eCRF according to laboratory 
requisition form. Refer to the Time and Events Schedule for the timing and frequency of all 
sample collections. Instructions for the collection, handling, and shipment of biomarker 
samples are found in the “Sample Collection and Handling Manual” that will be provided 
separately for sample collection and handling. 
9. 
SUBJECT COMPLETION/WITHDRAWAL 
9.1. 
Study Completion 
A subject will be considered to have completed the study if assessments have been completed 
until PSA Progression Visit. Subjects that have discontinued treatment for any reason will keep 
on the Follow-up Phase. There is an expected data collection period of up to 24 months per 
patient after enrollment to monitor survival status and, if applicable, subsequent prostate cancer 
therapy. 
9.2. 
Discontinuation of Study Treatment  
Discontinuation of a study drug will not result in automatic withdrawal from the study. 
A subject should ordinarily be maintained on study treatment until PSA progression as defined 
Section 8.2.2.1. 
However, a subject's study treatment may be discontinued for: 
x Radiographic progression as per RECIST v1.1 
x Clinical Progression defined as: 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
34 
Approved, Date: 19 February 2018  
o Deterioration in ECOG performance status to grade 3 or higher  
o Need to initiate any of the following because of tumor progression (even in the 
absence of radiographic evidence of disease)  
 Anticancer therapy for prostate cancer 
 Radiation therapy 
 Surgical interventions for complications due to tumor progression 
x Dosing noncompliance or delay the start of next cycle for more than 4 weeks (due to 
toxicity) 
x Withdrawal of consent for continued treatment  
x The investigator believes that for safety reasons (eg, adverse event) it is in the best interest 
of the subject to stop treatment. All attempts to obtain imaging studies at the time of 
treatment discontinuation should be made to assess for radiographic progression.  
x Study data will continue to be collected after discontinuation of treatment, unless the 
subject withdraws consent for further study participation. 
9.3. 
Withdrawal from the Study  
A subject will be withdrawn from the study for any of the following reasons: 
x Lost to follow-up  
x Withdrawal of consent for subsequent data collection 
If a patient is lost to follow up, all possible efforts must be made by the study site personnel to 
contact the subject and to determine endpoint status and the reason for the 
discontinuation/withdrawal. The measures taken for follow up must be documented. The 
informed consent will stipulate that even if a subject decides to discontinue the study drug, he 
will agree to be contacted periodically by the investigator to assess endpoint status.  
When a subject withdraws before completing the study, the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study drug assigned to the withdrawn 
subject may not be re-assigned to another subject. Subjects who withdraw will not be replaced. 
10. 
STATISTICAL METHODS 
Statistical analysis will be performed by the sponsor or under the supervision of the sponsor. 
A general description of the statistical methods to be used to analyze the efficacy and safety 
data is outlined below.  
Unless otherwise specified, all continuous endpoints will be summarized using descriptive 
statistics, which will include the number of subjects, mean, standard deviation, median, 
minimum, and maximum. All categorical endpoints will be summarized using frequencies and 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
35 
Approved, Date: 19 February 2018  
percentages. The baseline measurement will be the last value on or before the date of first study 
treatment. 
Interim analysis could be performed during this study. 
10.1. 
Subject Information 
The ITT population will include all subjects who enter onto this multicenter, single-arm, phase 
II study.  
Subject disposition, demographic and baseline characteristics will be performed on data from 
the ITT population. 
The safety population will include all subjects who receive at least 1 dose of any study drug. 
All baseline characteristics, treatment exposure, safety, toxicity and laboratory test analysis 
will be run on this database. 
The efficacy population will include all eligible subjects who receive at least one dose of any 
study drug. All efficacy tables will be run on this database. 
10.2. 
Sample Size Determination 
We assumed that the medium time to PSAP of Abiraterone plus prednisone in CRPC patients, 
which had failed to DES therapy, would be 8.5 months as in historical data with DES and 
ketoconazole1-3. A 5 months time to PSAP is the minimum effect to consider drug activity in 
this setting such as first-line chemotherapy4,5. Considering an uniform accrual over 1 year 
enrollment period, 6 months follow-up time and exponentially distributed PSAP times, a two-
sided test for the median7 with an alpha level of 0.05 and a power of 80%, 40 patients would 
need to be enrolled. In addition, considering a drop-out rate of 10%, a total sample size of 45 
patients is planned for the study. 
10.3. 
Demographics and Baseline Characteristics 
Demographic variables will include age, race, height, and weight. Baseline disease 
characteristics will include time from diagnosis, number of prior hormonal therapies, and other 
clinical characteristics as documented in the e-CRF. 
10.4. 
Efficacy Analyses 
Efficacy endpoints are described in Section 8.2.2. 
All continuous variables will be summarized using number of subjects (n), mean, standard 
deviation, median, minimum and maximum values. Categorical variables will be summarized 
using frequencies and percentages. All efficacy endpoints will be analyzed using the efficacy 
analysis population. 
Distributions of time-to-event will be estimated using the Kaplan-Meier product limit method 
and will be graphically displayed. The median times to event with two-sided 95% confidence 
intervals will be estimated. Non-stratified analysis will be conducted. Cox proportional hazards 
regression models will be used to evaluate potential covariates that may affect the estimates of 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
36 
Approved, Date: 19 February 2018  
event-free survival time. The covariate effect will be estimated using a hazard ratio and its 95% 
confidence interval obtained from these models. 
Response rate variable will be the proportion of patients fulfilling the respective criteria for 
response and will be reported with the 95% exact confidence limits for the binomial proportion.  
Additional exploratory analyses may be performed if deemed necessary. 
10.5. 
Biomarker Analyses 
Biomarker studies are designed to confirm prior findings in asymptomatic or mildly 
symptomatic metastatic castration-resistant prostate cancer. SA analyses will be conducted on 
blood samples from entire study population and serum samples for correlative translational 
research will be collected at 3 time points (baseline, week 12 and at the time of PSA 
progression/ end of study) from all subjects. 
The associations of SA with clinical response or time-to-event endpoints will be assessed using 
the appropriate statistical methods (logistic regression model or survival model will be used), 
depending on the endpoint. Other clinical covariates (such as age, tumor burden) may also be 
included in the model. Correlation of baseline expression levels with response or time-to-event 
endpoints will identify responsive (or resistant) subgroups. Biomarker results might be reported 
separately from the clinical study report due to its exploratory nature. 
10.6. 
Safety Analyses 
Subjects who receive at least 1 dose of any study drug will be analyzed for safety. The safety 
parameters to be evaluated are the incidence, intensity, and type of adverse events, clinically 
significant changes in the subject’s physical examination findings, vital signs measurements, 
and clinical laboratory results. Exposure to study drug and reasons for discontinuation of study 
treatment will be tabulated. 
Adverse Events 
The verbatim terms used in the eCRF by investigators to identify adverse events will be coded 
using the Medical Dictionary for Regulatory Activities (MedDRA) and will be graded 
according to the NCI-CTCAE, Version 4.0. Treatment-emergent adverse events are those 
events that occur or worsen on or after first dose of study drug through 30 days post last dose 
and will be included in the analysis. Adverse events will be summarized by system organ class 
and preferred term, and will be presented overall. Serious adverse events and deaths will be 
provided in a listing. All adverse events resulting in discontinuation, dose modification, dosing 
interruption, or treatment delay of study drug will also be listed and tabulated by preferred 
term. 
Clinical Laboratory Tests 
Clinical laboratory test results will be collected from screening until PSA Progression Visit. 
Laboratory data will be summarized by type of laboratory test using descriptive statistics at 
each measurement time point. Parameters with predefined NCI-CTCAE, Version 4, toxicity 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
37 
Approved, Date: 19 February 2018  
grades will be summarized. Change from baseline to the worst adverse event grade experienced 
by the subject during the study will be provided as shift tables. 
Vital Signs and Physical Examination 
Descriptive statistics of BP (systolic and diastolic) values and changes from baseline will be 
summarized at each scheduled time point. The percentage of subjects with values beyond 
clinically important limits will be summarized. Descriptive statistics of changes from baseline 
in physical examinations will be summarized at each scheduled time point. 
11. 
ADVERSE EVENT REPORTING 
Timely, accurate, and complete reporting and analysis of safety information from clinical 
studies are crucial for the protection of subjects, investigators, and the sponsor, and are 
mandated by regulatory agencies worldwide. The sponsor has established Standard Operating 
Procedures in conformity with regulatory requirements worldwide to ensure appropriate 
reporting of safety information; all clinical studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures. 
11.1. 
Definitions 
11.1.1. 
Adverse Event Definitions and Classifications 
Adverse Event 
An adverse event (AE) is any untoward medical occurrence in a clinical study subject 
administered a medicinal (investigational or non-investigational) product. An adverse event 
does not necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and unintended sign (including an abnormal finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational or non-investigational) 
product, whether or not related to that medicinal (investigational or non-investigational) 
product. (Definition per International Committee on Harmonisation [ICH]) 
This includes any occurrence that is new in onset or aggravated in severity or frequency from 
the baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities. 
Note: The sponsor collects adverse events starting with the signing of the informed consent 
form (refer to Section 11.3.1, All Adverse Events, for time of last adverse event recording). 
Serious Adverse Event (SAE) 
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any untoward medical occurrence that at any dose: 
x Results in death  
x Is life-threatening (The subject was at risk of death at the time of the event. It does not refer 
to an event that hypothetically might have caused death should it have been more severe.)  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
38 
Approved, Date: 19 February 2018  
x Requires inpatient hospitalization or prolongation of existing hospitalization  
x Results in persistent or significant disability/incapacity  
x Is a congenital anomaly/birth defect  
x Is a suspected transmission of any infectious agent via a medicinal product  
x Is medically important*  
*Medical and scientific judgment should be exercised in deciding whether expedited reporting 
is also appropriate in other situations, such as important medical events that may not be 
immediately life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually be considered serious. 
Unlisted (Unexpected) Adverse Event/Reference Safety Information 
An AE is considered unlisted when the nature or severity is not consistent with the applicable 
product reference safety information. For an investigational product, the expectedness of an 
adverse event will be determined by whether or not it is listed in the Investigator's Brochure. 
Adverse Event Associated With the Use of the Drug 
An adverse event is considered associated with the use of the drug when the attribution is 
possible, probable, or very likely by the definitions listed in Section 11.1.2. 
11.1.2. 
Attribution Definitions 
Not Related 
An adverse event that is not related to the use of the drug. 
Doubtful 
An adverse event for which an alternative explanation is more likely, eg, concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is 
unlikely. 
Possible 
An adverse event that might be due to the use of the drug. An alternative explanation, eg, 
concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded. 
Probable 
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely, eg, concomitant 
drug(s), concomitant disease(s). 
Very Likely 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
39 
Approved, Date: 19 February 2018  
An adverse event that is listed as a possible adverse reaction and cannot be reasonably 
explained by an alternative explanation, eg, concomitant drug(s), concomitant disease(s). The 
relationship in time is very suggestive (eg, it is confirmed by dechallenge and rechallenge). 
11.1.3. 
Severity Criteria 
The NCI-CTCAE v4.0 will be used to grade the severity of adverse events. 
Any adverse event not listed in the CTCAE will be graded as follows: 
Grade 1, Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort 
and not interfering with everyday activities. 
Grade 2, Moderate: Sufficient discomfort is present to cause interference with normal 
activity. 
Grade 3, Severe: Extreme distress, causing significant impairment of functioning or 
incapacitation. Prevents normal everyday activities. 
Grade 4, Life-threatening: Urgent intervention indicated.  
Grade 5, Death: Death. 
The investigator should use clinical judgment in assessing the severity of events not directly 
experienced by the subject (eg, laboratory abnormalities). 
11.2. 
Special Reporting Situations 
Safety events of interest on a sponsor medicinal product that may require expedited reporting 
or safety evaluation include, but are not limited to: 
x Overdose of a sponsor medicinal product  
x Suspected abuse/misuse of a sponsor medicinal product  
x Inadvertent or accidental exposure to a sponsor medicinal product  
x Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor medicinal product, eg, name confusion)  
Special reporting situations should be recorded in the eCRF. Any special reporting situation 
that meets the criteria of a serious adverse event should be recorded on the serious adverse 
event page of the eCRF.  
11.3. 
Procedures  
11.3.1. 
All Adverse Events 
All AEs and special reporting situations, whether serious or non-serious, will be reported from 
the time a signed and dated informed consent form is obtained until 30 days after last dose of 
study drug. Serious adverse events, including those spontaneously reported to the investigator 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
40 
Approved, Date: 19 February 2018  
within 30 days after the last dose of study drug, must be reported using the Serious Adverse 
Event Form. The sponsor will evaluate any safety information that is spontaneously reported 
by an investigator beyond the time frame specified in the protocol. 
All AEs, regardless of seriousness, severity, or presumed relationship to study therapy, must 
be recorded using medical terminology in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg, cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory infection"). Investigators must record in the eCRF their opinion concerning the 
relationship of the adverse event to study therapy. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions. 
The sponsor assumes responsibility for appropriate reporting of adverse events to the 
regulatory authorities. The sponsor will also report to the investigator all serious adverse events 
that are unlisted (unexpected) and associated with the use of the drug. The investigator (or 
sponsor where required) must report these events to the appropriate Independent Ethics 
Committee/Institutional Review Board (IEC/IRB) that approved the protocol unless otherwise 
required and documented by the IEC/IRB. 
Subjects (or their designees, when appropriate) must be provided with a "study card" indicating 
the following: 
x Subject's name  
x Subject number  
x Subject's data of birth  
x Study site number  
x Investigator's name and 24-hour contact information  
x Local sponsor's name and 24-hour contact information  
x Statement that the subject is participating in a clinical study  
Clinical Laboratory Adverse Events 
All clinically important abnormal laboratory tests occurring during the study will be repeated 
at appropriate intervals until they return either to baseline or to a level deemed acceptable by 
the investigator and the Sponsor’s medical monitor (or his/her designated representative), or 
until a diagnosis that explains them is made. The criteria for determining whether an abnormal 
laboratory test result should be reported as an adverse event are as follows: 
x Test result is associated with accompanying symptoms, or 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
41 
Approved, Date: 19 February 2018  
x Test result requires additional diagnostic testing or medical/surgical intervention (merely 
repeating an abnormal test, in the absence of any of the above conditions, does not meet 
criteria for reporting as an adverse event), or 
x Test result leads to a change in study dosing or discontinuation from the study, significant 
additional concomitant drug treatment or other therapy, or 
x Test result leads to any of the outcomes included in the definition of a serious adverse event, 
or 
x Test result is considered to be an adverse event by the investigator or Sponsor. 
Any abnormal test result that is determined to be an error does not require reporting as an 
adverse event, even if it did meet one of the above conditions except for Condition 4. Clinically 
significant laboratory results must be recorded in the subject’s eCRF. 
11.3.2. 
Serious Adverse Events 
All serious adverse events occurring during clinical studies must be reported to the appropriate 
sponsor contact person by investigational staff within 24 hours of their knowledge of the event. 
Information regarding serious adverse events will be transmitted to the sponsor using the 
Serious Adverse Event Form, which must be completed and signed by a member of the 
investigational staff, and transmitted to the sponsor within 24 hours. The initial and follow-up 
reports of a serious adverse event should be made by facsimile (fax). 
All serious adverse events that have not resolved by the end of the study, or that have not 
resolved upon discontinuation of the subject's participation in the study, must be followed until 
any of the following occurs: 
x The event resolves  
x The event stabilizes  
x The event returns to baseline, when a baseline value/status is available  
x The event can be attributed to agents other than the study drug or to factors unrelated to 
study conduct  
x It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow-up after demonstration 
of due diligence with follow-up efforts)  
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in a clinical study must be reported as 
a serious adverse event, except hospitalizations for the following: 
x Social reasons in the absence of an adverse event  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
42 
Approved, Date: 19 February 2018  
x Surgery or procedure planned before entry into the study (must be documented in the 
eCRF)  
Disease progression should not be recorded as an adverse event or serious adverse event term; 
instead, signs and symptoms of clinical sequelae resulting from disease progression/lack of 
efficacy will be reported when they fulfill the serious adverse event definition (see Section 
11.1.1).  
During the follow-up phase of the study, deaths regardless of causality and serious adverse 
events thought to be related to study drug will be collected and reported within 24 hours of 
discovery or notification of the event and documented.  
11.3.3. 
Pregnancy 
Because the effect of the study drug on sperm is unknown, pregnancies in partners of male 
subjects included in the study will be reported by the investigational staff within 24 hours of 
their knowledge of the event using the appropriate pregnancy notification form. 
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in 
the infant will be required. 
11.3.4. 
Contacting Sponsor Regarding Safety 
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safety issues or questions regarding the study are listed on the Contact Information 
page(s), which will be provided as a separate document. 
12. 
PRODUCT QUALITY COMPLAINT HANDLING 
A product quality complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, i.e., any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. PQCs may 
have an impact on the safety and efficacy of the product. Timely, accurate, and complete 
reporting and analysis of PQC information from clinical studies are crucial for the protection 
of subjects, investigators, and the sponsor, and are mandated by regulatory agencies worldwide. 
The sponsor has established procedures in conformity with regulatory requirements worldwide 
to ensure appropriate reporting of PQC information; all clinical studies conducted by the 
sponsor or its affiliates will be conducted in accordance with those procedures. 
12.1. 
Procedures 
All initial PQCs must be reported to the sponsor by the investigational staff as soon as possible 
after being made aware of the event. 
If the defect is combined with a serious adverse event, then the investigational staff must report 
the PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 11.3.2). A sample of the suspected product should be maintained for further 
investigation when requested by the sponsor. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
43 
Approved, Date: 19 February 2018  
12.2. 
Contacting Sponsor Regarding Product Quality 
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality issues are listed on the Contact Information page(s), which will be 
provided as a separate document. 
13. 
STUDY DRUG INFORMATION 
13.1. 
Physical Description of Study Drug(s) 
Abiraterone acetate 250 mg tablets are oval, white to off-white and contain abiraterone acetate 
and compendial (USP/NF/EP) grade lactose monohydrate, microcrystalline cellulose, 
croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon 
dioxide, and purified water, in descending order of concentration (the water is removed during 
tableting). 
13.2. 
Packaging 
The study drugs will be packaged in individual subject kits. Subjects will be provided with a 
30-day supply to allow for visits to occur every 28 days with a + 2 day window. Study drug 
will be dispensed in child-resistant packaging. 
13.3. 
Labeling 
Study drug labels will contain information to meet the applicable regulatory requirements. 
13.4. 
Preparation, Handling, and Storage 
The study drugs must be stored in a secure area and administered only to subjects entered into 
the clinical study in accordance with the conditions specified in this protocol. Study drugs 
should be stored at room temperature. Additional information is provided in the abiraterone 
acetate Investigator’s Brochure. 
13.5. 
Drug Accountability 
The investigator is responsible for ensuring that all study drug received at the site is inventoried 
and accounted for throughout the study. The dispensing of study drug to the subject, and the 
return of study drug from the subject, must be documented on the drug accountability form. 
Subjects must be instructed to return all original containers, whether empty or containing study 
drug. These requirements also apply to prednisone capsules supplied by the sponsor. 
All study drugs must be handled in strict accordance with the protocol and the container label, 
and must be stored at the study site in a limited-access area or in a locked cabinet under 
appropriate environmental conditions. Unused study drug, and study drug returned by the 
subject, must be available for verification by the sponsor's site monitor during on-site 
monitoring visits. The return to the sponsor of unused study drug, or used returned study drug 
for destruction, will be documented on the drug return form. When the site is an authorized 
destruction unit and study drug supplies are destroyed on site, this must also be documented 
on the drug return form. 
All study drugs should be dispensed under the supervision of the investigator or a qualified 
member of the investigational staff, or by a hospital/clinic pharmacist. Study drug will be 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
44 
Approved, Date: 19 February 2018  
supplied only to subjects participating in the study. Returned study drug must not be dispensed 
again, even to the same subject. Whenever a subject brings his study drug to the site for pill 
count, this is not seen as a return of supplies. Study drug may not be relabeled or reassigned 
for use by other subjects. The investigator agrees neither to dispense the study drug from, nor 
store it at, any site other than the study sites agreed upon with the sponsor. 
14. 
STUDY-SPECIFIC MATERIALS 
The investigator will be provided with the following supplies: 
x Investigator Brochure  
x Pharmacy manual/site investigational product procedures manual  
x Sample Collection and Handling manual  
x eCRF 
x BPI-SF Questionnaire 
15. 
ETHICAL ASPECTS 
15.1. 
Study-Specific Design Considerations 
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and 
may be withdrawn at any time with no reason given and without penalty or loss of benefits to 
which they would otherwise be entitled. Only subjects who are fully able to understand the 
risks, benefits, and potential adverse events of the study, and provide their consent voluntarily 
will be enrolled. 
Ongoing medical review is completed by the sponsor.  
The blood volume to be collected is approximately 5 to 10 mL per study visit. For subjects 
participating in the correlative translational study, the blood volumes will be 5 a 10 mL per 
study visit.  
Subjects will receive low-dose prednisone 5mg/day. The prednisone dose used in this study is 
lower than the prednisone 10mg/day dose used in other abiraterone acetate Phase 3 studies 
COU-AA-301 and COU-AA-302 that enrolled advanced symptomatic mCRPC patients. The 
higher prednisone dose in other Phase 3 studies was selected because it is commonly used as 
the standard of care in combination with approved chemotherapy agents or as monotherapy for 
palliation of symptoms in advanced prostate cancer patients. The required use of prednisone in 
combination with abiraterone acetate is to help mitigate the symptoms of mineralocorticoid 
excess caused by CYP17 inhibition, which is the mechanism of action of abiraterone acetate. 
Data from early Phase 1/2 studies with abiraterone acetate in patients with mCRPC demonstrate 
that dexamethasone 0.5mg once daily (equivalent to prednisone dose of 3.33 mg once daily) 
was effective in mitigating the mineralocorticoid effects of abiraterone acetate1-3.  The protocol 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
45 
Approved, Date: 19 February 2018  
allows for the dose of prednisone to be increased to 10 mg/day if required to manage 
mineralocorticoid toxicities. 
15.2. 
Regulatory Ethics Compliance  
15.2.1. 
Investigator Responsibilities 
The investigator is responsible for ensuring that the clinical study is performed in accordance 
with the protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable 
regulatory and country-specific requirements. 
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and well-being 
of study subjects are protected, consistent with the principles that originated in the Declaration 
of Helsinki, and that the clinical study data are credible. 
15.2.2. 
Independent Ethics Committee or Institutional Review Board 
Before the start of the study, the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents: 
x Final protocol and, when applicable, amendments  
x Sponsor-approved informed consent form (and any other written materials to be provided 
to the subjects)  
x Investigator's Brochure (or equivalent information) and amendments/addenda  
x Sponsor-approved subject recruiting materials  
x Information on compensation for study-related injuries or payment to subjects for 
participation in the study, when applicable  
x Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB)  
x Information regarding funding, name of the sponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for subjects  
x Any other documents that the IEC/IRB requests to fulfill its obligation 
This study will be undertaken only after the IEC/IRB has given full approval of the final 
protocol, any amendments, the informed consent form, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly identify the IEC/IRB and the documents being 
approved.  
During the study the investigator (or sponsor where required) will send the following 
documents and updates to the IEC/IRB for their review and approval, where appropriate:  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
46 
Approved, Date: 19 February 2018  
x Protocol amendments 
x Revision(s) to informed consent form and any other written materials to be provided to 
subjects  
x When applicable, new or revised subject recruiting materials approved by the sponsor  
x Revisions to compensation for study-related injuries or payment to subjects for 
participation in the study, when applicable  
x New edition(s) of the Investigator's Brochure and amendments/addenda  
x Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annually)  
x Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
investigational drug  
x New information that may adversely affect the safety of the subjects or the conduct of the 
study  
x Deviations from or changes to the protocol to eliminate immediate hazards to the subjects  
x Report of deaths of subjects under the investigator's care  
x Notification when a new investigator is responsible for the study at the site  
x Development Safety Update Report and Line Listings, where applicable  
x Any other requirements of the IEC/IRB 
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable informed 
consent form revisions must be submitted promptly to the IEC/IRB for review and approval 
before implementation of the change(s).  
At least once a year, the IEC/IRB will be asked to review and reapprove this clinical study. The 
reapproval should be documented in writing (excluding the ones that are purely administrative, 
with no consequences for subjects, data, or study conduct).  
At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB 
about the study completion.  
15.2.3. 
Informed Consent 
Each subject must give written consent according to local requirements after the nature of the 
study has been fully explained. The consent form must be signed before performance of any 
study-related activity. The consent form that is used must be approved by both the sponsor and 
by the reviewing IEC/IRB and be in a language that the subject can read and understand. The 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
47 
Approved, Date: 19 February 2018  
informed consent should be in accordance with principles that originated in the Declaration of 
Helsinki, current ICH and GCP guidelines, applicable regulatory requirements, and sponsor 
policy. 
Before enrollment in the study, the investigator or an authorized member of the investigational 
staff must explain to potential subjects the aims, methods, reasonably anticipated benefits, and 
potential hazards of the study, and any discomfort participation in the study may entail. 
Subjects will be informed that their participation is voluntary and that they may withdraw 
consent to participate at any time. They will be informed that choosing not to participate will 
not affect the care the subject will receive for the treatment of his disease. Subjects will be told 
that alternative treatments are available should they refuse to take part and that such refusal 
will not prejudice future treatment. Finally, they will be told that the investigator will maintain 
a subject identification register for the purposes of long-term follow up when needed and that 
their records may be accessed by health authorities and authorized sponsor staff without 
violating the confidentiality of the subject, to the extent permitted by the applicable law(s) or 
regulations. By signing the informed consent form the subject is authorizing such access, and 
agrees to allow his study physician to recontact the subject for the purpose of obtaining consent 
for additional safety evaluations, and subsequent disease-related treatments or to obtain 
information about his survival status. 
The subject will be given sufficient time to read the informed consent form and the opportunity 
to ask questions. After this explanation and before entry into the study, consent should be 
appropriately recorded by means of the subject's personally dated signature. After having 
obtained the consent, a copy of the informed consent form must be given to the subject. 
If the subject is unable to read or write, then an impartial witness should be present for the 
entire informed consent process (which includes reading and explaining all written 
information) and should personally date and sign the informed consent form after the oral 
consent of the subject is obtained. 
15.2.4. 
Privacy of Personal Data 
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to fulfill the objectives of the study. 
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must 
be put in place. Sponsor personnel whose responsibilities require access to personal data agree 
to keep the identity of study subjects confidential. 
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator to allow direct access to his original medical records for 
study-related monitoring, audit, IEC/IRB review, and regulatory inspection. This consent also 
addresses the transfer of the data to other entities and to other countries. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
48 
Approved, Date: 19 February 2018  
The subject has the right to request through the investigator access to his personal data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps will 
be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study, and the applicable laws and regulations. 
15.2.5. 
Country Selection 
This study will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product, unless explicitly addressed as a specific ethical 
consideration in Section 15.1. 
16. 
ADMINISTRATIVE REQUIREMENTS 
16.1. 
Protocol Amendments 
Neither the investigator nor the sponsor will modify this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated 
by the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly submitted to the IEC/IRB and relevant competent authority. 
Documentation of amendment approval by the investigator and IEC/IRB must be provided to 
the sponsor or its designee. When the change(s) involves only logistic or administrative aspects 
of the study, the IRB (and IEC where required) only needs to be notified. 
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page(s) provided separately). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. 
In all cases, contact with the sponsor must be made as soon as possible to discuss the situation 
and agree on an appropriate course of action. The data recorded in the eCRF and source 
documents will reflect any departure from the protocol, and the source documents will describe 
this departure and the circumstances requiring it. 
16.2. 
Regulatory Documentation 
16.2.1. 
Regulatory Approval/Notification 
This protocol and any amendment(s) must be submitted to the appropriate regulatory 
authorities in each respective country, when applicable. A study may not be initiated until all 
local regulatory requirements are met. 
16.2.2. 
Required Prestudy Documentation 
The following documents must be provided to the sponsor before shipment of study drug to 
the investigational site: 
x Protocol and any amendment(s), signed and dated by the principal investigator  
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
49 
Approved, Date: 19 February 2018  
x A copy of the dated and signed, written IEC/IRB approval of the protocol, amendments, 
informed consent form, any recruiting materials, and when applicable, subject 
compensation programs. This approval must clearly identify the specific protocol by title 
and number and must be signed by the chairman or authorized designee.  
x Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, then a general statement may be substituted for this list. If an 
investigator or a member of the investigational staff is a member of the IEC/IRB, then 
documentation must be obtained to state that this person did not participate in the 
deliberations or in the vote/opinion of the study.  
x Regulatory authority approval or notification, when applicable  
x Signed and dated statement of investigator (eg, Form FDA 1572), when applicable  
x Documentation of investigator qualifications (eg, curriculum vitae)  
x Completed investigator financial disclosure form from the principal investigator, where 
required  
x Signed and dated clinical trial agreement, which includes the financial agreement  
x Any other documentation required by local regulations 
The following documents must be provided to the sponsor before enrollment of the first 
subject:  
x Completed investigator financial disclosure forms from all clinical subinvestigators  
x Documentation of subinvestigator qualifications (eg, curriculum vitae)  
x Name and address of any local laboratory conducting tests for the study, and a dated copy 
of current laboratory normal ranges for these tests, when applicable  
x Local laboratory documentation demonstrating competence and test reliability (eg, 
accreditation/license), when applicable  
16.3. 
Subject Identification, Enrollment, and Screening Logs 
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study. This document will be reviewed by 
the sponsor site contact for completeness. 
The subject identification and enrollment log will be treated as confidential and will be filed 
by the investigator in the study file. To ensure subject confidentiality, no copy will be made. 
All reports and communications relating to the study will identify subjects by ID and date of 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
50 
Approved, Date: 19 February 2018  
birth. In cases where the subject is not randomized into the study, the date seen and the date of 
birth will be used. 
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study. 
16.4. 
Source Documentation 
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility, and study identification; study 
discussion and date of informed consent; dates of visits; results of safety and efficacy 
parameters as required by the protocol; record of all adverse events and follow-up of adverse 
events; concomitant medication; drug receipt/dispensing/return records; study drug 
administration information; and date of study completion and reason for early discontinuation 
of study drug or withdrawal from the study, when applicable. 
In addition, the author of an entry in the source documents should be identifiable. 
At a minimum, the type and level of detail of source data available for a study subject should 
be consistent with that commonly recorded at the site as a basis for standard medical care. 
Specific details required as source data for the study will be reviewed with the investigator 
before the study and will be described in the monitoring guidelines (or other equivalent 
document). 
16.5. 
Case Report Form Completion 
Case report forms are provided for each subject in electronic format. 
Electronic Data Capture (eDC) will be used for this study. The study data will be transcribed 
by study personnel from the source documents onto an eCRF, and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor and the site. The 
electronic file will be considered to be the eCRF. 
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documentation. All data relating to 
the study must be recorded in eCRFs prepared by the sponsor. Data must be entered into eCRFs 
in English. Designated site personnel must complete the eCRF as soon as possible after a 
subject visit, and the forms should be available for review at the next scheduled monitoring 
visit. 
Every effort should be made to ensure that all subjective measurements (eg, pain scale 
information) to be recorded in the eCRF are completed by the same individual who made the 
initial baseline determinations. The investigator must verify that all data entries in the eCRFs 
are accurate and correct. 
All eCRF entries, corrections, and alterations must be made by the investigator or other 
authorized study-site personnel. When necessary, queries will be generated in the eDC tool. 
The investigator or an authorized member of the investigational staff must adjust the eCRF 
(when applicable) and complete the query. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
51 
Approved, Date: 19 February 2018  
When corrections to an eCRF are needed after the initial entry into the eCRF, this can be done 
in 3 different ways: 
x Site personnel can make corrections in the eDC tool at their own initiative or as a response 
to an auto query (generated by the eDC tool)  
x Site manager can generate a query for resolution by the investigational staff  
x Clinical data manager can generate a query for resolution by the investigational staff  
16.6. 
Data Quality Assurance/Quality Control 
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the investigator 
and associated personnel before the study, and periodic monitoring visits by the sponsor. 
Written instructions will be provided for collection, preparation, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study personnel before 
the start of the study. The sponsor will review eCRFs for accuracy and completeness during 
on-site monitoring visits and after transmission to the sponsor; any discrepancies will be 
resolved with the investigator or designee, as appropriate. After upload of the data into the 
clinical study database they will be verified for accuracy and consistency with the data sources. 
16.7. 
Record Retention 
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all 
eCRFs and all source documents that support the data collected from each subject, as well as 
all study documents as specified in ICH/GCP Section 7, Essential Documents for the Conduct 
of a Clinical Trial, and all study documents as specified by the applicable regulatory 
requirement(s). The investigator/institution will take measures to prevent accidental or 
premature destruction of these documents. 
Essential documents must be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will 
be retained for a longer period when required by the applicable regulatory requirements or by 
an agreement with the sponsor. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained. 
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, then custody must be transferred to a person who 
will accept the responsibility. The sponsor must be notified in writing of the name and address 
of the new custodian. Under no circumstance shall the investigator relocate or dispose of any 
study documents before having obtained written approval from the sponsor. 
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, then the investigator must permit access to such reports. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
52 
Approved, Date: 19 February 2018  
16.8. 
Monitoring 
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will 
record dates of the visits in a study site visit log that will be kept at the site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRFs with the hospital or clinic records (source 
documents). The nature and location of all source documents will be identified to ensure that 
all sources of original data required to complete the eCRF are known to the sponsor and 
investigational staff and are accessible for verification by the sponsor site contact. If electronic 
records are maintained at the investigational site, then the method of verification must be 
discussed with the investigational staff. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verifying that the data recorded in the eCRF are consistent with the original source data. 
Findings from this review of eCRFs and source documents will be discussed with the 
investigational staff. The sponsor expects that, during monitoring visits, the relevant 
investigational staff will be available, the source documentation will be accessible, and a 
suitable environment will be provided for review of study-related documents. The monitor will 
meet with the investigator on a regular basis during the study to provide feedback on the study 
conduct. 
16.9. 
Study Completion/Termination  
16.9.1. 
Study Completion 
The study is considered completed with the last study assessment for the last subject 
participating in the study. The final data from the investigational site will be sent to the sponsor 
(or designee) after completion of the final subject assessment at that site, in the time frame 
specified in the Clinical Trial Agreement. 
16.9.2. 
Study Termination 
The sponsor reserves the right to close the investigational site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Investigational sites will be closed 
upon study completion. An investigational site is considered closed when all required 
documents and study supplies have been collected and a site closure visit has been performed. 
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of an investigational site by the sponsor or investigator may 
include but are not limited to: 
x Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines 
x Inadequate recruitment of subjects by the investigator 
x Discontinuation of further drug development 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
53 
Approved, Date: 19 February 2018  
x Patients do not reach PSAP after at least 24 months of treatment and do not show clinical 
progressive results for more than 12 months. 
16.10. On-Site Audits  
Representatives of the sponsor's clinical quality assurance department may visit the site at any 
time during or after completion of the study to conduct an audit of the study in compliance with 
regulatory guidelines and company policy. These audits will require access to all study records, 
including source documents, for inspection and comparison with the eCRFs. Subject privacy 
must, however, be respected. The investigator and staff are responsible for being present and 
available for consultation during routinely scheduled site audit visits conducted by the sponsor 
or its designees. Similar auditing procedures may also be conducted by agents of any regulatory 
body, either as part of a national GCP compliance program or to review the results of this study 
in support of a regulatory submission. The investigator should immediately notify the sponsor 
when they have been contacted by a regulatory agency concerning an upcoming inspection.  
16.11. Use of Information and Publication  
All information, including but not limited to information regarding abiraterone acetate or the 
sponsor's operations (e.g. patent application, formulas, manufacturing processes, basic 
scientific data, prior clinical data, formulation information) supplied by the sponsor to the 
investigator and not previously published, and any data, including exploratory biomarker data, 
generated as a result of this study, are considered confidential and remain the sole property of 
the sponsor. The investigator agrees to maintain this information in confidence and use this 
information only to accomplish this study, and will not use it for other purposes without the 
sponsor's prior written consent.  
The investigator understands that the information developed in the clinical study will be used 
by the sponsor in connection with the continued development of abiraterone acetate, and thus 
may be disclosed as required to other clinical investigators or regulatory agencies. To permit 
the information derived from the clinical studies to be used, the investigator is obligated to 
provide the sponsor with all data obtained in the study. 
The results of the study will be reported in a Clinical Study Report generated by the sponsor 
and will contain eCRF data from all investigational sites that participated in the study. 
Recruitment performance or specific expertise related to the nature and the key assessment 
parameters of the study will be used to determine a coordinating investigator. Results of 
exploratory biomarker analyses performed after the Clinical Study Report has been issued will 
be reported in a separate report and will not require a revision of the Clinical Study Report. 
Study subject identifiers will not be used in publication of exploratory biomarker results. Any 
work created in connection with performance of the study and contained in the data that can 
benefit from copyright protection (except any publication by the investigator as provided for 
below) shall be the property of the sponsor as author and owner of copyright in such work. 
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data 
and information without approval from the investigator. The investigator has the right to 
publish site-specific data after the primary data are published. If an investigator wishes to 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
54 
Approved, Date: 19 February 2018  
publish information from the study, then a copy of the manuscript must be provided to the 
sponsor for review at least 60 days before submission for publication or presentation. Expedited 
reviews will be arranged for abstracts, poster presentations, or other materials. If requested by 
the sponsor in writing, then the investigator will withhold such publication for up to an 
additional 60 days to allow for filing of a patent application. In the event that issues arise 
regarding scientific integrity or regulatory compliance, the sponsor will review these issues 
with the investigator. The sponsor will not mandate modifications to scientific content and does 
not have the right to suppress information. For multicenter study designs and substudy 
approaches, secondary results generally should not be published before the primary endpoints 
of a study have been published. Similarly, investigators will recognize the integrity of a 
multicenter study by not submitting for publication data derived from the individual site until 
the combined results from the completed study have been submitted for publication, within 12 
months of the availability of the final data (tables, listings, graphs), or the sponsor confirms 
there will be no multicenter study publication. Authorship of publications resulting from this 
study will be based on the guidelines on authorship, such as those described in the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals, which state that the named 
authors must have made a significant contribution to the design of the study or analysis and 
interpretation of the data, provided critical review of the paper, and given final approval of the 
final version. 
Registration of Clinical Studies and Disclosure of Results 
The sponsor will register or disclose the existence of and the results of clinical studies as 
required by law. 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
55 
Approved, Date: 19 February 2018  
REFERENCES 
 
1. 
Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone 
acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received 
prior ketoconazole therapy. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 2010;28:1481-8. 
2. 
Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with 
ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22:1025-33. 
3. 
Omlin A, C JP, Zaidi S, et al. Antitumour activity of abiraterone and diethylstilboestrol when 
administered sequentially to men with castration-resistant prostate cancer. British journal of cancer 
2013. 
4. 
Bosset PO, Albiges L, Seisen T, et al. Current role of diethylstilbestrol in the management of 
advanced prostate cancer. BJU international 2012;110:E826-9. 
5. 
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-Weekly versus 3-weekly 
docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The lancet 
oncology 2013;14:117-24. 
6. 
Saunders FJ. Some Aspects of Relation of Structure of Steroids to Their Prostate--Stimulating 
Effects. National Cancer Institute monograph 1963;12:139-59. 
7. 
Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan-17-
beta-ol-3-one by rat prostate. The Journal of biological chemistry 1968;243:5953-60. 
8. 
Labrie F, Dupont A, Belanger A, et al. New hormonal treatment in cancer of the prostate: 
combined administration of an LHRH agonist and an antiandrogen. Journal of steroid biochemistry 
1983;19:999-1007. 
9. 
Chay CH, Cooper CC, Hellerstedt BA, Pienta KJ. Antimetastatic drugs in prostate cancer. 
Clinical prostate cancer 2002;1:14-9. 
10. 
Mohler JL, Gaston KE, Moore DT, et al. Racial differences in prostate androgen levels in men 
with clinically localized prostate cancer. The Journal of urology 2004;171:2277-80. 
11. 
Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen 
therapy. Nature medicine 2004;10:33-9. 
12. 
Gregory CW, Johnson RT, Jr., Presnell SC, Mohler JL, French FS. Androgen receptor 
regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer 
xenograft. Journal of andrology 2001;22:537-48. 
13. 
Landry J, Marceau N. The relative rates of degradation of the plasma membrane glycoproteins 
from normal rat liver. Biochimica et biophysica acta 1975;389:154-61. 
14. 
Taplin ME, Ho SM. Clinical review 134: The endocrinology of prostate cancer. The Journal of 
clinical endocrinology and metabolism 2001;86:3467-77. 
15. 
Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel 
steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). The Journal 
of steroid biochemistry and molecular biology 1994;50:267-73. 
16. 
Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in 
metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer research 
2008;68:4447-54. 
17. 
O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-
hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. 
British journal of cancer 2004;90:2317-25. 
18. 
Acharya M, Bernard A, Gonzalez M, Jiao J, De Vries R, Tran N. Open-label, phase I, 
pharmacokinetic studies of abiraterone acetate in healthy men. Cancer chemotherapy and pharmacology 
2012;69:1583-90. 
19. 
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic 
prostate cancer. The New England journal of medicine 2011;364:1995-2005. 
20. 
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without 
previous chemotherapy. The New England journal of medicine 2013;368:138-48. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
56 
Approved, Date: 19 February 2018  
21. 
Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the 
androgen receptor therapeutically. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 2011;29:3651-8. 
22. 
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with 
progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer 
Clinical Trials Working Group. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 2008;26:1148-59. 
23. 
Klus GT, Nakamura J, Li JS, et al. Growth inhibition of human prostate cells in vitro by novel 
inhibitors of androgen synthesis. Cancer research 1996;56:4956-64. 
24. 
Peterson RE, Imperato-McGinley J, Gautier T, Sturla E. Male pseudohermaphroditism due to 
steroid 5-alpha-reductase deficiency. The American journal of medicine 1977;62:170-91. 
 
 
 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
57 
Approved, Date: 19 February 2018  
Attachment 1: SUMMARY OF RECIST CRITERIA VERSION 1.1 
The following information was extracted from Section 3, Section 4, and Appendix I of the New 
response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) authored 
by Eisenhauer et al (2009). Refer to the European Journal of Cancer article (2009;45(2):228-
247) for the complete publication. 
Measurability of tumor at baseline 
3.1 Definitions At baseline, tumor lesions/lymph nodes will be categorized measurable or 
non-measurable as follows: 
3.1.1 Measurable 
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of: 
- 10 mm by CT scan (CT scan slice thickness no greater than 5 mm) 
The following two methods of measure are not allowed in this protocol: 
- 10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measurable)  
- 20 mm by chest X-ray  
- Malignant lymph nodes: To be considered pathologically enlarged and measurable, a 
lymph node must be > 15 mm in short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm). At baseline and in follow-up, only 
the short axis will be measured and followed. See also ‘Baseline documentation of 
target and non-target lesions’ in section 4.2 of the RECIST guideline for information 
on lymph node measurement. 
3.1.2 Non-measurable 
All other lesions, including small lesions (longest diameter <10 mm or pathological lymph 
nodes with > 10 to <15 mm short axis) as well as truly non-measurable lesions. Lesions 
considered truly non-measurable include: leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
and abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques.  
3.2 Specifications by methods of measurements 
3.2.1 Measurement of lesions 
All measurements should be recorded in metric notation, using calipers if clinically assessed. 
All baseline evaluations should be performed as close as possible to the treatment start and 
never more than 4 weeks before the beginning of the treatment. 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
58 
Approved, Date: 19 February 2018  
3.2.2 Method of assessment 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging based evaluation 
should always be done rather than clinical examination. 
4. Tumor response evaluation 
4.1 Assessment of overall tumor burden and measurable disease 
To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for subsequent measurements. 
4.2 Baseline documentation of ‘target’ and ‘non-target’ lesions 
When more than one measurable lesion is present at baseline all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved 
organs should be identified as target lesions and will be recorded and measured at baseline (this 
means in instances where patients have only one or two organ sites involved a maximum of 
two and four lesions respectively will be recorded). For evidence to support the selection of 
only five target lesions, see analyses on a large prospective database in the article by Bogaerts 
et al. (Reference #10 in Eisenhauer publication). 
Target lesions should be selected on the basis of their size (lesions with the longest diameter), 
be representative of all involved organs, but in addition should be those that lend themselves 
to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion 
does not lend itself to reproducible measurement in which circumstance the next largest lesion, 
which can be measured reproducibly, should be selected. 
Lymph nodes merit special mention since they are normal anatomical structures, which may 
be visible by imaging even if not involved by tumor. As noted in Section 3, pathological nodes 
which are defined as measurable and may be identified as target lesions must meet the criterion 
of a short axis of > 15 mm by CT scan. Only the short axis of these nodes will contribute to the 
baseline sum. The short axis of the node is the diameter normally used by radiologists to judge 
if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the 
plane in which the image is obtained (for CT scan this is almost always the axial plane; for 
MRI the plane of acquisition may be axial, sagittal or coronal). The smaller of these measures 
is the short axis. For example, an abdominal node which is reported as being 20 mm x 30 mm 
has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 
mm should be recorded as the node measurement (See also the example in Fig. 4 in Appendix 
II of the Eisenhauer reference). All other pathological nodes (those with short axis > 10 mm 
but <15 mm) should be considered non-target lesions. Nodes that have a short axis <10 mm 
are considered non-pathological and should not be recorded or followed. 
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum. The baseline 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
59 
Approved, Date: 19 February 2018  
sum diameters will be used as reference to further characterize any objective tumor regression 
in the measurable dimension of the disease. 
All other lesions (or sites of disease) including pathological lymph nodes should be identified 
as non- target lesions and should also be recorded at baseline. Measurements are not required 
and these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal 
progression’ (more details to follow). In addition, it is possible to record multiple nontarget 
lesions involving the same organ as a single item on the case record form (e.g. ‘multiple 
enlarged pelvic lymph nodes’ or ‘multiple liver metastases’). 
4.3 Response criteria 
This section provides the definitions of the criteria used to determine objective tumor response 
for target lesions. 
4.3.1 Evaluation of target lesions 
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm. 
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum diameters. 
Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking 
as reference the smallest sum on study (this includes the baseline sum if that is the smallest on 
study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered 
progression). 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for progressive disease, taking as reference the smallest sum diameters while on study. 
4.3.2 Special notes on the assessment of target lesions 
Lymph nodes. Lymph nodes identified as target lesions should always have the actual short 
axis measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the nodes regress to below 10 mm on study. This means that when lymph 
nodes are included as target lesions, the ‘sum’ of lesions may not be zero even if complete 
response criteria are met, since a normal lymph node is defined as having a short axis of <10 
mm. Case report forms or other data collection methods may therefore be designed to have 
target nodal lesions recorded in a separate section where, in order to qualify for CR, each node 
must achieve a short axis <10 mm. For PR, SD and progressive disease, the actual short axis 
measurement of the nodes is to be included in the sum of target lesions. 
Target lesions that become ‘too small to measure’. While on study, all lesions (nodal and non-
nodal) recorded at baseline should have their actual measurements recorded at each subsequent 
evaluation, even when very small (eg 2 mm). However, sometimes lesions or lymph nodes 
which are recorded as target lesions at baseline become so faint on CT scan that the radiologist 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
60 
Approved, Date: 19 February 2018  
may not feel comfortable assigning an exact measure and may report them as being ‘too small 
to measure’. When this occurs it is important that a value be recorded on the CRF. If it is the 
opinion of the radiologist that the lesion has likely disappeared, the measurement should be 
recorded as 0 mm. If the lesion is believed to be present and is faintly seen but too small to 
measure, a default value of 5 mm should be assigned (Note: It is less likely that this rule will 
be used for lymph nodes since they usually have a definable size when normal and are 
frequently surrounded by fat such as in the retroperitoneum; however, if a lymph node is 
believed to be present and is faintly seen but too small to measure, a default value of 5 mm 
should be assigned in this circumstance as well). This default value is derived from the 5 mm 
CT slice thickness (but should not be changed with varying CT slice thickness). The 
measurement of these lesions is potentially non- reproducible; therefore providing this default 
value will prevent false responses or progressions based upon measurement error. To reiterate, 
however, if the radiologist is able to provide an actual measure, that should be recorded, even 
if it is below 5 mm. 
Lesions that split or coalesce on treatment. When non-nodal lesions ‘fragment’, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion 
sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in 
obtaining maximal diameter measurements of each individual lesion. If the lesions have truly 
coalesced such that they are no longer separable, the vector of the longest diameter in this 
instance should be the maximal longest diameter for the ‘coalesced lesion’. 
4.3.3 Evaluation of non-target lesions 
This section provides the definitions of the criteria used to determine the tumor response for 
the group of non-target lesions. While some non-target lesions may actually be measurable, 
they need not be measured and instead should be assessed only qualitatively at the timepoints 
specified in the protocol. 
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (<10 mm short axis). 
Non-CR/Non-progressive disease: Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits. 
Progressive Disease: Unequivocal progression (see comments below) of existing non-target 
lesions. (Note: the appearance of one or more new lesions is also considered progression). 
4.3.4 Special notes on assessment of progression of non-target disease 
The concept of progression of non-target disease requires additional explanation as 
follows: 
When the patient also has measurable disease. In this setting, to achieve ‘unequivocal 
progression’ on the basis of the non-target disease, there must be an overall level of substantial 
worsening in non-target disease such that, even in presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest 
‘increase’ in the size of one or more non-target lesions is usually not sufficient to quality for 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
61 
Approved, Date: 19 February 2018  
unequivocal progression status. The designation of overall progression solely on the basis of 
change in non-target disease in the face of SD or PR of target disease will therefore be 
extremely rare. 
When the patient has only non-measurable disease. This circumstance arises in some studies 
when it is not a criterion of study entry to have measurable disease. The same general concepts 
apply here as noted above, however, in this instance there is no measurable disease assessment 
to factor into the interpretation of an increase in non-measurable disease burden. Because 
worsening in non-target disease cannot be easily quantified (by definition: if all lesions are 
truly non-measurable) a useful test that can be applied when assessing patients for unequivocal 
progression is to consider if the increase in overall disease burden based on the change in non-
measurable disease is comparable in magnitude to the increase that would be required to declare 
progressive disease for measurable disease: i.e. an increase in tumor burden representing an 
additional 73% increase in ‘volume’ (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as ‘sufficient to require a change in therapy.’ If ‘unequivocal progression’ is seen, 
the patient should be considered to have had overall progressive disease at that point. While it 
would be ideal to have objective criteria to apply to non-measurable disease, the very nature of 
that disease makes it impossible to do so, therefore the increase must be substantial. 
4.3.5 New lesions 
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection of new lesions are important. There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal: i.e. not attributable to differences in scanning technique, change in imaging 
modality or findings thought to represent something other than tumor (for example, some ‘new’ 
bone lesions may be simply healing or flare of pre-existing lesions). This is particularly 
important when the patient’s baseline lesions show partial or complete response. For example, 
necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic lesion, which 
it is not. 
A lesion identified on a follow-up study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. An example of this 
is the patient who has visceral disease at baseline and while on study has a CT or MRI brain 
ordered which reveals metastases. The patient’s brain metastases are considered to be evidence 
of progressive disease even if he/she did not have brain imaging at baseline. 
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there 
is definitely a new lesion, then progression should be declared using the date of the initial scan. 
4.4.1 Timepoint response 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
62 
Approved, Date: 19 February 2018  
It is assumed that at each protocol specified timepoint, a response assessment occurs. Table 1 
in this attachment provides a summary of the overall response status calculation at each 
timepoint for patients who have measurable disease at baseline. 
When patients have non-measurable (therefore non-target) disease only, Table 2 in this 
attachment is to be used. 
4.4.2 Missing assessments and inevaluable designation 
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable (NE) at that timepoint. If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered NE at that timepoint, unless a convincing 
argument can be made that the contribution of the individual missing lesion(s) would not 
change the assigned timepoint response. This would be most likely to happen in the case of 
progressive disease. For example, if a patient had a baseline sum of 50 mm with three measured 
lesions and at follow-up only two lesions were assessed, but those gave a sum of 80 mm, the 
patient will have achieved progressive disease status, regardless of the contribution of the 
missing lesion. 
4.4.3 Best overall response: all timepoints 
The best overall response is determined once all the data for the patient is known. 
Best response determination in studies where confirmation of complete or partial response IS 
NOT required: Best response in these studies is defined as the best response across all 
timepoints (for example, a patient who has SD at first assessment, PR at second assessment, 
and progressive disease on last assessment has a best overall response of PR). When SD is 
believed to be best response, it must also meet the protocol specified minimum time from 
baseline. If the minimum time is not met when SD is otherwise the best timepoint response, 
the patient’s best response depends on the subsequent assessments. For example, a patient who 
has SD at first assessment, progressive disease at second and does not meet minimum duration 
for SD, will have a best response of progressive disease. The same patient lost to follow-up 
after the first SD assessment would be considered inevaluable. 
 
Table 1: Timepoint Response: patients with Target (+/- no target) disease 1 
 
 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
63 
Approved, Date: 19 February 2018  
 
Table 2: Timepoint Response: patients with non-target disease only i 
 
 
 
 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
64 
Approved, Date: 19 February 2018  
Attachment 2: ECOG PERFORMANCE STATUS 
 
 
Based on published in Am. J. Clin. Oncol23,24..: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And 
Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982. The Eastern 
Cooperative Oncology Group, Robert Comis M.D., Group Chair 
 
 
 
 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
65 
Approved, Date: 19 February 2018  
Attachment 3: NEW YORK HEART FAILURE CRITERIA 
The following table presents the New York Heart Association classification of cardiac disease: 
 
 
Reference 23,24: American Heart Association. Classes of heart failure. Available at 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-
Failure_UCM_306328_Article.jsp. Accessed September 6, 2011. 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
66 
Approved, Date: 19 February 2018  
Attachment 4: ADDITIONAL INFORMATION ON CYP450 DRUG INTERACTIONS 
http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractio
nsla beling/ucm093664.htm 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx 
 
 
 
NCT02217566

JNJ-212082 (abiraterone acetate)  
 
Clinical Protocol 212082PCR2036  
67 
Approved, Date: 19 February 2018  
INVESTIGATOR AGREEMENT 
I have read this protocol and agree that it contains all necessary details for carrying out this study. I will 
conduct the study as outlined herein and will complete the study within the time designated. 
I will provide copies of the protocol and all pertinent information to all individuals responsible to me 
who assist in the conduct of this study. I will discuss this material with them to ensure that they are fully 
informed regarding the study drug, the conduct of the study, and the obligations of confidentiality. 
Coordinating Investigator (where required): 
Name (typed or printed):
Institution and Address:
Signature:
Date:
(Day Month Year) 
 
Principal (Site) Investigator: 
Name (typed or printed):
Institution and Address:
Telephone Number:
Signature:
Date:
(Day Month Year) 
 
Sponsor's Responsible Medical Officer: 
Name (typed or printed):
Rosemarie Gidekel
Institution:
Janssen Research & Development 
Signature:
Date:
(Day Month Year) 
 
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by the investigator to the sponsor, and a protocol amendment will not be required. 
 
 
ROSEMARIE
GIDEKEL
Digitally signed by ROSEMARIE GIDEKEL 
DN: c=US, o=JNJ, ou=Subscribers, 0.9.2342.19200300.100.1.1=1060888, 
cn=ROSEMARIE GIDEKEL 
Reason: I attest to the accuracy and integrity of this document. 
Date: 2018.02.23 16:28:17 -03'00' 
Adobe Reader version: 11.0.10
NCT02217566